



(11) **EP 2 770 066 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
09.03.2016 Bulletin 2016/10

(51) Int Cl.:
C12Q 1/68 (2006.01) G01N 33/53 (2006.01)

(21) Application number: **14161006.3**

(22) Date of filing: **22.10.2009**

(54) **Compositions and methods for detecting mutations in JAK2 nucleic acid**

Zusammensetzungen und Verfahren zur Detektion von Mutationen in JAK2-Nucleinsäure

Compositions et procédés pour détecter des mutations dans un acide nucléique JAK2

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: **31.10.2008 US 110501 P**
15.07.2009 US 503318

(43) Date of publication of application:
27.08.2014 Bulletin 2014/35

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
09824031.0 / 2 340 315

(73) Proprietor: **Quest Diagnostics Investments Incorporated**
Wilmington, DE 19899 (US)

(72) Inventors:
• **Albitar, Maher**
Coto de Caza, CA 92679 (US)
• **Ma, Wanlong**
Aliso Viejo, CA 92656 (US)

(74) Representative: **Schiweck, Weinzierl & Koch**
European Patent Attorneys
Landsberger Straße 98
80339 München (DE)

(56) References cited:
US-A1- 2007 248 961

- **ELENA ALBIERO ET AL: "A new TMHA-DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders", AMERICAN JOURNAL OF HEMATOLOGY, vol. 83, no. 7, 1 July 2008 (2008-07-01), pages 603-604, XP055131400, ISSN: 0361-8609, DOI: 10.1002/ajh.21116**
- **SMITH C A ET AL: "The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms", HUMAN PATHOLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 39, no. 6, 1 June 2008 (2008-06-01), pages 795-810, XP022693901, ISSN: 0046-8177, DOI: 10.1016/J.HUMPATH.2008.02.004 [retrieved on 2008-06-03]**
- **BESSES CARLOS ET AL: "JAK2 mutations at exon 12 and 14 in polycythemia vera and idiopathic erythrocytosis: Incidence and correlation with clinical characteristics", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, no. 11, part 1, 1 November 2007 (2007-11-01), page 746A, XP009157146, ISSN: 0006-4971**
- **M INAMI ET AL: "Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia", LEUKEMIA, vol. 22, no. 1, 1 January 2008 (2008-01-01), pages 216-216, XP055131403, ISSN: 0887-6924, DOI: 10.1038/sj.leu.2404953**
- **TEFFERI A: "JAK and MPL mutations in myeloid malignancies", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 49, no. 3, 1 March 2008 (2008-03-01), pages 388-397, XP009157130, ISSN: 1042-8194, DOI: 10.1080/10428190801895360**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 770 066 B1

- MA WANLONG ET AL: "Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias", JOURNAL OF MOLECULAR DIAGNOSTICS, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, BETHESDA, MD, US, vol. 11, no. 1, 1 January 2009 (2009-01-01), pages 49-53, XP009115055, ISSN: 1525-1578, DOI: 10.2353/JMOLDX.2009.080114
- LEE TAI-SUNG ET AL: "Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations", BMC STRUCTURAL BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 9, no. 1, 10 September 2009 (2009-09-10), page 58, XP021058180, ISSN: 1472-6807, DOI: 10.1186/1472-6807-9-58
- MA WANLONG ET AL: "Splice Variant JAK2 Transcript Deleting Exon 14 in Patients with Chronic Myeloproliferative Neoplasms", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 114, no. 22, 1 November 2009 (2009-11-01), XP009179314, ISSN: 0006-4971
- WANLONG MA ET AL: "JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms", PLOS ONE, vol. 5, no. 8, 13 August 2010 (2010-08-13), page e12165, XP055131407, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0012165

Description

FIELD OF THE INVENTION

5 **[0001]** This invention relates to the field of disease detection and more specifically to compositions and diagnostic methods useful for patients having hematopoietic disorders such as a myeloproliferative disease.

BACKGROUND OF THE INVENTION

10 **[0002]** The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention and is not admitted to describe or constitute prior art to the invention.

[0003] The Janus kinases are a family of tyrosine kinases that play a role in cytokine signaling. For example, JAK2 kinase acts as an intermediary between membrane-bound cytokine receptors such as the erythropoietin receptor (EpoR), and down-stream members of the signal transduction pathway such as STAT5 (Signal Transducers and Activators of Transcription protein 5). See, e.g., Schindler, C.W., J. Clin Invest. 109:1133-1137 (2002); Tefferi and Gilliland, Mayo Clin. Proc. 80:947-958 (2005); Giordanetto and Kroemer, Protein Engineering, 15(9):727-737 (2002). JAK2 is activated when cytokine receptor/ligand complexes phosphorylate the associated JAK2 kinase. *Id.* JAK2 can then phosphorylate and activate its substrate molecule, for example STAT5, which enters the nucleus and interacts with other regulatory proteins to affect transcription. *Id.*; Nelson, M.E., and Steensma, D.P., Leuk. Lymphoma 47:177-194 (2006).

20 **[0004]** Certain hematopoietic diseases including non-CML myeloproliferative diseases (MPDs) such as polycythemia vera (PV), essential thrombocythemia (ET), and chronic idiopathic myelofibrosis (IMF) and as of yet unclassified myeloproliferative diseases (MPD-NC) are characterized by an aberrant increase in blood cells. See e.g., Vainchenker and Constantinescu, Hematology (American Society of Hematology), 195-200 (2005). This increase is generally initiated by a spontaneous mutation in a multipotent hematopoietic stem cell located in the bone marrow. *Id.* Due to the mutation, the stem cell produces far more blood cells of a particular lineage than normal, resulting in the overproduction of cells such as erythroid cells, megakaryocytes, granulocytes and monocytes. Some symptoms common to patients with MPD include enlarged spleen, enlarged liver, elevated white, red and/or platelet cell count, blood clots (thrombosis), weakness, dizziness and headache. Diseases such as PV, ET and IMF may presage leukemia, however the rate of transformation (e.g., to blast crisis) differs with each disease. *Id.* It has long been postulated that perturbation of protein tyrosine kinase (PTK) signaling by mutations and other genetic alterations is associated with MPDs. Mutant PTKs such as, for example, Janus kinase 2 (JAK2) gene mutations, can lead to constitutive activity in patients with MPDs.

25 **[0005]** The specific gene and concomitant mutation or mutations responsible for many MPDs is not known. However, a mutation in the Janus kinase 2 (JAK2) gene, a cytoplasmic, nonreceptor tyrosine kinase, has been identified in a number of MPDs (Smith, C.A. et al., Human Pathology, 39:795-810 (2008)). The discovery of the JAK2 V617F mutation was a milestone in unveiling the molecular pathogenesis of MPDs. For example, this mutation has been reported in up to 97% of patients with PV, and in greater than 40% of patients with either ET or IMF. See e.g., Baxter et al., Lancet 365:1054-1060 (2005); James et al., Nature 438:1144-1148 (2005); Zhao, et al., J. Biol. Chem. 280(24):22788-22792 (2005); Levine et al., Cancer Cell, 7:387-397 (2005); Kralovics, et al., New Eng. J. Med. 352(17):1779-1790 (2005); Jones, et al., Blood 106:2162-2168 (2005); Steensma, et al., Blood 106:1207-2109 (2005).

30 **[0006]** A variety of different approaches and a large body of evidence suggest that, when present, the JAK2 V617F mutation contributes to the pathogenesis of MPD. See e.g., Kaushansky, Hematology (Am Soc Hematol Educ Program), 533-7 (2005). The mutation has been detected from blood samples, bone marrow and buccal samples (see, e.g., Baxter et al., Lancet 365:1054-1060 (2005); James et al., Nature 438:1144-1148 (2005); Zhao, et al., J. Biol. Chem. 280(24):22788-22792 (2005); Levine et al., Cancer Cell, 7:387-397 (2005); Kralovics, et al., New Eng. J. Med. 352(17):1779-1790 (2005)), and homozygous and heterozygous cell populations have been reported in MPD patients. Baxter et al., Lancet 365:1054-1060 (2005).

35 **[0007]** The JAK2 V617F substitution, which is located in the pseudokinase domain of JAK2, relieves the auto-inhibition of its kinase activity, leading to a constitutively active kinase and augments downstream JAK2-STAT signaling pathways (see e.g., Saharinen et al., Mol Cell Biol 20:3387-3395 (2000); Saharinen et al., Mol. Biol Cell 14:1448-1459 (2003)). Other JAK2 mutations in humans including translocations, point mutations, deletions, and insertions have been reported. See e.g., Scott et al., N Engl J Med 356:459-468 (2007); Li et al., Blood 111:3863-3866 (2008).

40 **[0008]** In addition, mutations in the JAK2 exon 14 were found to be associated with myeloproliferative disorders (Albiero et al., American J. of Hematology 83(7):603-604 (2008), while mutations in exons 12 and 14 were found in polycythemia vera, idiopathic erythrocytosis and Philadelphia chromosome positive leukemia (Besses et al., Blood, American Society of Hematology 110(10 part 1):746a (2007); Inami et al., Leukemia 22(1):216 (2008)).

SUMMARY OF THE INVENTION

5 [0009] The invention is based on the identification of previously unknown mutations in the JAK2 gene and JAK2 protein. Specifically, the JAK2 gene and corresponding protein mutations of the invention result from the deletion of exon 14 of the JAK2 gene. The invention further provides compositions and methods useful in the diagnosis and prognosis of hematopoietic diseases including, for example, myeloproliferative diseases.

10 [0010] In one aspect, the invention provides an isolated nucleic acid of at least 17 nucleotides of SEQ ID NO: 1, wherein said isolated nucleic acid comprises the mutation wherein nucleotides 2271-2358 (exon 14 deletion) are deleted, wherein said isolated nucleic acid is less than 5000 nucleotides in length. In one embodiment, the isolated nucleic acid includes at least one additional mutation shown in Table 2. In another embodiment, the isolated nucleic acid is labeled with a detectable label.

15 [0011] In a second aspect, the invention provides a polypeptide of at least 10 contiguous amino acids of SEQ ID NO: 2 in which amino acid S593-N622 are deleted, wherein said polypeptide is less than 1100 amino acids. In one embodiment, the polypeptide includes at least one additional mutation shown in Table 2. In another embodiment, the fragment is labeled with a detectable label.

20 [0012] In another aspect, the invention provides a method for detecting a hematopoietic disease comprising: detecting the presence or absence of a JAK2 mutation using a biological sample obtained from the individual. The method comprises a) evaluating a sample from the individual for the presence or absence of one or more mutations in JAK2 nucleic acid or JAK2 polypeptide, wherein said mutation in the JAK2 nucleic acid is a deletion of nucleotides 2271-2358 (exon 14) and the mutation in the JAK2 polypeptide is the deletion of amino acids S593-N622; and b) identifying the individual as having a hematopoietic disease when the JAK2 nucleic acid comprises at least one of the mutations.

25 [0013] Disclosed is also a method of determining a prognosis of an individual diagnosed with a hematopoietic disease, the method comprising: (a) determining the presence or absence of deletion of nucleotides 2271-2358 (exon 14) in a JAK2 nucleic acid; and (b) identifying the individual as having poor prognosis when the mutation is present in the JAK2 nucleic acid sample.

[0014] Disclosed is also a method for selecting therapy for an individual with a hematopoietic disorder comprising evaluating a sample containing nucleic acids from the individual for the presence or absence of deletion of nucleotides 2271-2358 (exon 14) in JAK2 nucleic acid and selecting the therapy based on mutations in JAK2 nucleic acid.

30 [0015] In some embodiments of any of the above aspects, the JAK2 nucleic acid is RNA. In other embodiments of any of the above aspects of the invention, the presence or absence of one or more mutations may be determined relative to SEQ ID NO: 1. In certain embodiments of any of the above aspects of the invention, the JAK2 nucleic acid includes one or more further mutations shown in Table 2.

35 [0016] In still other embodiments of any of the above aspects, evaluating or determining the presence or absence of a mutation in a JAK2 nucleic acid sample includes amplifying JAK2 nucleic acid and hybridizing the amplified JAK2 nucleic acid with a detection oligonucleotide that is capable of specifically detecting a JAK2 nucleic acid mutant sequence under hybridization conditions. In other embodiments of any of the above aspects of the invention, evaluating or determining the presence or absence of one or more mutations in a JAK2 nucleic acid sample includes amplifying JAK2 nucleic acid and performing direct sequencing analysis of the amplified nucleic acid.

40 [0017] Disclosed is also a method for diagnosing a hematopoietic disease in an individual comprising: a) evaluating a sample containing polypeptides from the individual for the presence or absence of one or more mutations in JAK2 polypeptide in which one or more mutations is selected from the group consisting of the mutations of Table 2, and b) identifying the individual as having a hematopoietic disease when the JAK2 polypeptide comprises at least one of the mutations.

45 [0018] Disclosed is also a method of determining a prognosis of an individual diagnosed with a hematopoietic disease, the method comprising: (a) determining the presence or absence of one or more mutations in a JAK2 polypeptide sample in which one or more mutations is selected from the group consisting of the mutations of Table 2; and (b) identifying the individual as having poor prognosis when one or more mutations are present in the JAK2 polypeptide.

50 [0019] Disclosed is also a method for selecting therapy for an individual with a hematopoietic disorder comprising evaluating a sample containing polypeptides from the individual for the presence or absence of one or more mutations in JAK2 polypeptide in which one or more mutations is selected from the group consisting of the mutations shown in Table 2 and selecting the therapy based on mutations in JAK2 polypeptide.

55 [0020] In some embodiments of the above aspects, the presence or absence of one or more mutations may be determined relative to SEQ ID NO: 2. In certain embodiments of the above aspects, the JAK2 polypeptide includes one or more additional mutations shown in Table 2. In certain embodiments of the above aspects, evaluating a sample or determining the presence or absence of one or more mutations in a JAK2 polypeptide sample includes using an antibody that specifically binds to the mutated JAK2 polypeptide.

[0021] In some embodiments of any of the above aspects, the JAK2 nucleic acid and/or polypeptide sample is from a biological fluid from the patient, preferably the sample is blood, serum, or plasma.

[0022] In certain embodiments of any of the above aspects of the invention, the disease is a myeloproliferative disease; more preferably, the myeloproliferative disease is polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, or an unclassified myeloproliferative disease.

5 [0023] The term "neoplastic disease" refers to a condition characterized by an abnormal growth of new cells such as a tumor. A neoplasm includes solid and non-solid tumor types such as a carcinoma, sarcoma, leukemia and the like. A neoplastic disease may be malignant or benign.

10 [0024] The term "myeloproliferative disease (MPD)" or "myeloproliferative disorder" is meant to include non-lymphoid dysplastic or neoplastic conditions arising from a hematopoietic stem cell or its progeny. "MPD patient" includes a patient who has been diagnosed with an MPD. "Myeloproliferative disease" is meant to encompass the specific, classified types of myeloproliferative diseases including polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). Also included in the definition are hypereosinophilic syndrome (HES), chronic neutrophilic leukemia (CNL), myelofibrosis with myeloid metaplasia (MMM), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia, chronic basophilic leukemia, chronic eosinophilic leukemia, and systemic mastocytosis (SM). "Myeloproliferative disease" is also meant to encompass any unclassified myeloproliferative diseases (UMPD or MPD-NC).

15 [0025] As used herein the terms "diagnose" or "diagnosis" or "diagnosing" refer to distinguishing or identifying a disease, syndrome or condition or distinguishing or identifying a person having a particular disease, syndrome or condition.

20 [0026] "Determining a prognosis" as used herein refers to the process in which the course or outcome of a condition in a patient is predicted. The term "prognosis" does not refer to the ability to predict the course or outcome of a condition with 100% accuracy. Instead, the term refers to identifying an increased or decreased probability that a certain course or outcome will occur in a patient exhibiting a given condition/marker, when compared to those individuals not exhibiting the condition. The nature of the prognosis is dependent upon the specific disease and the condition/marker being assessed. For example, a prognosis may be expressed as the amount of time a patient can be expected to survive, the likelihood that the disease goes into remission, or to the amount of time the disease can be expected to remain in remission.

25 [0027] As used herein, the term "treatment," "treating," or "treat" refers to care by procedures or application that are intended to relieve illness or injury. Although it is preferred that treating a condition or disease such as a myeloproliferative disease will result in an improvement of the condition, the term treating as used herein does not indicate, imply, or require that the procedures or applications are at all successful in ameliorating symptoms associated with any particular condition. Treating a patient may result in adverse side effects or even a worsening of the condition which the treatment was intended to improve.

30 [0028] By "subject" is meant a human or any other animal which contains a JAK2 gene that can be amplified using the primers and methods described herein. A subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease. A human includes pre and post natal forms.

35 [0029] As used herein, the term "patient" refers to one who receives medical care, attention or treatment. As used herein, the term is meant to encompass a person diagnosed with a disease such as myeloproliferative disease as well as a person who may be symptomatic for a disease but who has not yet been diagnosed.

40 [0030] The term "sample" or "patient sample" is meant to include biological samples such as tissues and bodily fluids. "Bodily fluids" may include, but are not limited to, blood, serum, plasma, saliva, cerebral spinal fluid, pleural fluid, tears, lactal duct fluid, lymph, sputum, urine, amniotic fluid, and semen. A sample may include a bodily fluid that is "acellular." An "acellular bodily fluid" includes less than about 1% (w/w) whole cellular material. Plasma or serum are examples of acellular bodily fluids. A sample may include a specimen of natural or synthetic origin.

45 [0031] The term "nucleic acid" or "nucleic acid sequence" refers to an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, which may be single or double stranded, and represent the sense or antisense strand. A nucleic acid may include DNA or RNA, and may be of natural or synthetic origin. For example, a nucleic acid may include mRNA, genomic DNA or cDNA. Nucleic acid may include nucleic acid that has been amplified (e.g., using polymerase chain reaction). The convention "NTwt###NTmut" is used to indicate a mutation that results in the wild-type nucleotide NTwt at position ### in the nucleic acid being replaced with mutant NTmut.

50 [0032] For the JAK2 nucleic acid sequence, a "mutation" means a JAK2 nucleic acid sequence that includes at least one nucleic acid variation as compared to reference sequence GenBank accession number NM_004972 (SEQ ID NO: 1). A mutation in JAK2 nucleic acid may result in a change in the encoded polypeptide sequence or the mutation may be silent with respect to the encoded polypeptide sequence. A change in an amino acid sequence may be determined as compared to SEQ ID NO: 2, as a reference amino acid sequence.

55 [0033] The term "zygosity status" as used herein refers to a sample, a cell population, or an organism as appearing heterozygous, homozygous, or hemizygous as determined by testing methods known in the art and described herein. The term "zygosity status of a nucleic acid" means determining whether the source of nucleic acid appears heterozygous, homozygous, or hemizygous. The "zygosity status" may refer to differences in a single nucleotide in a sequence. In some methods, the zygosity status of a sample with respect to a single mutation may be categorized as homozygous wild-type, heterozygous (*i.e.*, one wild-type allele and one mutant allele), homozygous mutant, or hemizygous (*i.e.*, a

single copy of either the wild-type or mutant allele). Because direct sequencing of plasma or cell samples as routinely performed in clinical laboratories does not reliably distinguish between hemizygoty and homozygoty, in some embodiments, these classes are grouped. For example, samples in which no or a minimal amount of wild-type nucleic acid is detected are termed "hemizygous/homozygous mutant." In some embodiments, a "minimal amount" may be between about 1-2%. In other embodiments, a minimal amount may be between about 1-3%. In still other embodiments, a "minimal amount" may be less than 1%.

[0034] The term "substantially all" as used herein means at least about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or 100%.

[0035] "Substantially pure" as used herein in the context of nucleic acid represents at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% of the nucleic acid in a sample. The nucleic acid sample may exist in solution or as a dry preparation.

[0036] By "isolated", when referring to a nucleic acid (e.g., an oligonucleotide such as RNA, DNA, or a mixed polymer) is meant a nucleic acid that is apart from a substantial portion of the genome in which it naturally occurs and/or is substantially separated from other cellular components which naturally accompany such nucleic acid. For example, any nucleic acid that has been produced synthetically (e.g., by serial base condensation) is considered to be isolated. Likewise, nucleic acids that are recombinantly expressed, cloned, produced by a primer extension reaction (e.g., PCR), or otherwise excised from a genome are also considered to be isolated.

[0037] As used herein, a "fragment" means a polynucleotide that is at least about 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 200, 300, 400, 500, 1000 nucleotides or more in length.

[0038] "Specific hybridization" is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after any subsequent washing steps. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may occur, for example, at 65°C in the presence of about 6xSSC. Stringency of hybridization may be expressed, in part, with reference to the temperature under which the wash steps are carried out. Such temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Equations for calculating T_m and conditions for nucleic acid hybridization are known in the art.

[0039] By "substantially complementary" is meant that two sequences that will specifically hybridize. The skilled artisan will understand that substantially complementary sequences need not hybridize along their entire length.

[0040] Oligonucleotides used as primers or probes for specifically amplifying (*i.e.*, amplifying a particular target nucleic acid sequence) or specifically detecting (*i.e.*, detecting a particular target nucleic acid sequence) a target nucleic acid generally are capable of specifically hybridizing to the target nucleic acid.

[0041] The term "oligonucleotide" is understood to be a molecule that has a sequence of bases on a backbone comprised mainly of identical monomer units at defined intervals. The bases are arranged on the backbone in such a way that they can enter into a bond with a nucleic acid having a sequence of bases that are complementary to the bases of the oligonucleotide. The most common oligonucleotides have a backbone of sugar phosphate units. A distinction may be made between oligodeoxyribonucleotides that do not have a hydroxyl group at the 2' position and oligoribonucleotides that have a hydroxyl group in this position. Oligonucleotides also may include derivatives, in which the hydrogen of the hydroxyl group is replaced with organic groups, e.g., an allyl group. Oligonucleotides of the method which function as primers or probes are generally at least about 10-15 nucleotides long and more preferably at least about 15 to 25 nucleotides long, although shorter or longer oligonucleotides may be used in the method. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. The oligonucleotide may be generated in any manner, including, for example, chemical synthesis, DNA replication, reverse transcription, PCR, or a combination thereof. The oligonucleotide may be modified. For example, the oligonucleotide may be labeled with an agent that produces a detectable signal (e.g., a fluorophore).

[0042] The term "detectable label" as used herein refers to a molecule or a compound or a group of molecules or a group of compounds associated with a nucleic acid or a polypeptide and is used to identify the nucleic acid or the polypeptide. In some cases, the detectable label may be detected directly. In other cases, the detectable label may be a part of a binding pair, which can then be subsequently detected. Signals from the detectable label may be detected by various means and will depend on the nature of the detectable label. Detectable labels may be isotopes, fluorescent moieties, colored substances, and the like. Examples of means to detect detectable label include but are not limited to spectroscopic, photochemical, biochemical, immunochemical, electromagnetic, radiochemical, or chemical means, such as fluorescence, chemifluorescence, or chemiluminescence, or any other appropriate means.

[0043] By "antibody that specifically binds to the mutated JAK2 polypeptide" is meant that the antibody preferentially binds to mutated JAK2 polypeptide and not to the wild type JAK2 polypeptide. Preferential binding of the antibody is meant to include at least 90% of the times the antibody will bind to mutated JAK2 polypeptide and discriminate between mutated and wild type JAK2 polypeptides.

[0044] As used herein, the term "activation domain" in reference to JAK2 refers generally to a domain involved in cell activation such as, for example, cell proliferation. An example of an activation domain is a kinase or pseudokinase domain.

[0045] As used herein, the term "pseudokinase domain" refers to a portion of a polypeptide or nucleic acid that encodes a portion of the polypeptide, where the portion shows homology to a functional kinase but possesses no catalytic activity.

A pseudokinase domain may also be referred to as a "kinase-like domain." An example of a pseudokinase domain is the JAK2 pseudokinase domain, also termed the JH2 domain. The N-terminal part of JAK2 pseudokinase domain (JH2) is a regulatory domain that negatively regulates the activity of JAK2.

[0046] The term "kinase domain" refers to a portion of a polypeptide or nucleic acid that encodes a portion of the polypeptide, where the portion is required for kinase activity of the polypeptide (e.g., tyrosine kinase activity).

[0047] In some methods of the invention, mutations may "affect JAK2 kinase activity." The affected JAK2 kinase activity may include kinase activity that increases, decreases, becomes constitutive, stops completely or affects greater, fewer or different targets. A mutation that affects kinase activity may be present in a kinase domain or in a domain associated with a kinase domain such as the JAK2 pseudokinase domain.

[0048] As used herein, the term "including" has the same meaning as the term comprising.

BRIEF DESCRIPTION OF THE FIGURES

[0049]

FIG. 1 is a series of representative sequencing chromatograms of Exon 13 mutations (FIG. 1A), Exon 14 deletion (FIG. 1B), and Exon 15 mutation (FIG. 1C). Arrows indicate positions of mutant nucleotides and dots indicate deleted nucleotides.

FIG. 2 is a schematic diagram of the JAK2 gene structure with some of the mutated residues in exons 12-15 shown.

DETAILED DESCRIPTION OF THE INVENTION

[0050] The present invention is based on the discovery of previously unknown mutations in the JAK2 nucleic acid and protein which have been associated with myeloproliferative diseases. The mutations of the present invention comprise the deletion of exon 14 corresponding to nucleotides 2271-2358 of SEQ ID NO: 1.

JAK2 nucleic acid

[0051] JAK2 genomic nucleic acid is located in human chromosome 9. Exemplary sequences of human JAK2 genomic sequences include but are not limited to GenBank Accession numbers: NG_009904, CM000260, CM000671, GL000069..

[0052] Exemplary sequences of all or portions of human JAK2 mRNA include but are not limited to GenBank Accession numbers: NM_004972, human JAK2 mRNA. Exemplary sequence of JAK2 mRNA is provided in SEQ ID NO: 1.

[0053] The JAK2 nucleic acids of this invention include, for example, nucleic acids that are substantially identical to a portion of the JAK2 nucleotide sequence of SEQ ID NO: 1 and further comprise the deletion of exon 14 (nucleotides 2271-2358). In some embodiments, the JAK2 nucleic acids have at least 10, 12, 14, 16, 18, 20, 25, 30, 40, 50, 75, 100, or more nucleotides in length. In some other embodiments, the JAK2 nucleic acids are less than 6000, 5000, 4000, 3000, 2000, 1000, 750, 500, 400, 300, or 200 nucleotides in length.

Biological Sample Collection and Preparation

[0054] The methods and compositions of this invention may be used to detect mutations in the JAK2 gene and/or JAK2 protein using a biological sample obtained from an individual. The nucleic acid (DNA or RNA) may be isolated from the sample according to any methods well known to those of skill in the art. If necessary the sample may be collected or concentrated by centrifugation and the like. The cells of the sample may be subjected to lysis, such as by treatments with enzymes, heat, surfactants, ultrasonication, or a combination thereof. The lysis treatment is performed in order to obtain a sufficient amount of nucleic acid derived from the individual's cells to detect using polymerase chain reaction. Alternatively, mutations in the JAK2 gene may be detected using an acellular bodily fluid according to the methods described in U.S. Patent Application 11/408,241 (Publication No. US 2007-0248961).

Plasma or Serum Preparation Methods

[0055] Methods of plasma and serum preparation are well known in the art. Either "fresh" blood plasma or serum, or frozen (stored) and subsequently thawed plasma or serum may be used. Frozen (stored) plasma or serum should

optimally be maintained at storage conditions of -20 to -70 degrees centigrade until thawed and used. "Fresh" plasma or serum should be refrigerated or maintained on ice until used, with nucleic acid (e.g., RNA, DNA or total nucleic acid) extraction being performed as soon as possible. Exemplary methods are described below.

5 Nucleic Acid Extraction and Amplification

[0056] The nucleic acid to be amplified may be from a biological sample such as an organism, cell culture, tissue sample, and the like. The biological sample can be from a subject which includes any animal, preferably a mammal. A preferred subject is a human, which may be a patient presenting to a medical provider for diagnosis or treatment of a disease. The biological sample may be obtained from a stage of life such as a fetus, young adult, adult, and the like. Particularly preferred subjects are humans being tested for the existence of a JAK2 mutation.

[0057] Various methods of extraction are suitable for isolating the DNA or RNA. Suitable methods include phenol and chloroform extraction. See Maniatis et al., *Molecular Cloning, A Laboratory Manual*, 2d, Cold Spring Harbor Laboratory Press, page 16.54 (1989). Numerous commercial kits also yield suitable DNA and RNA including, but not limited to, QIAamp™ mini blood kit, Agencourt Genfind™, Roche Cobas® Roche MagNA Pure® or phenol:chloroform extraction using Eppendorf Phase Lock Gels®, and the NucliSens extraction kit (Biomerieux, Marcy l'Etoile, France). In other methods, mRNA may be extracted from patient blood/bone marrow samples using MagNA Pure LC mRNA HS kit and Mag NA Pure LC Instrument (Roche Diagnostics Corporation, Roche Applied Science, Indianapolis, IN).

[0058] Numerous methods are known in the art for isolating total nucleic acid, DNA and RNA from blood, serum, plasma and bone marrow or other hematopoietic tissues. In fact, numerous published protocols, as well as commercial kits and systems are available. By way of example but not by way of limitation, examples of such kits, systems and published protocols are described below. Commercially available kits include Qiagen products such as the QiaAmp DNA Blood MiniKit (Cat.# 51104, Qiagen, Valencia, CA), the QiaAmp RNA Blood MiniKit (Cat.# 52304, Qiagen, Valencia, CA); Promega products such as the Wizard Genomic DNA Kit (Cat.# A1620, Promega Corp. Madison, WI), Wizard SV Genomic DNA Kit (Cat.# A2360, Promega Corp. Madison, WI), the SV Total RNA Kit (Cat.# X3100, Promega Corp. Madison, WI), PolyAtract System (Cat.# Z5420, Promega Corp. Madison, WI), or the PurYield RNA System (Cat.# Z3740, Promega Corp. Madison, WI).

Extraction of RNA from Plasma or Serum

[0059] Plasma RNA is highly sensitive and may replace DNA-based testing because of the relative abundance of the RNA and the ease in detecting deletions such as, for example, deletion of Exon 14. Circulating extracellular deoxyribonucleic acid (DNA), including tumor-derived or associated extracellular DNA, is also present in plasma and serum. See Stroun, M., et al., *Oncology* 46:318-322, (1989). Since this DNA will additionally be extracted to varying degrees during the RNA extraction methods described above, it may be desirable or necessary (depending upon clinical objectives) to further purify the RNA extract and remove trace DNA prior to proceeding to further RNA analysis. This may be accomplished using DNase, for example by the method as described by Rashtchian, A., *PCR Methods Applic.* 4:S83-S91, (1994), as follows.

[0060] Glass beads, Silica particles or Diatom Extraction: RNA may be extracted from plasma or serum using silica particles, glass beads, or diatoms, as in the method or adaptations of Boom, R., et al., *J. Clin. Micro.* 28:495-503, (1990); Cheung, R. C., et al., *J. Clin. Micro.* 32:2593-2597, (1994).

[0061] Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction: As an alternative method, RNA may be extracted from plasma or serum using the Acid Guanidinium Thiocyanate-Phenol-chloroform extraction method described by Chomczynski, P. and Sacchi, N., *Analytical Biochemistry* 162:156-159, (1987), as follows.

[0062] Alternative Nucleic Acid Extraction Methods: Alternative methods may be used to extract RNA from body fluids including but not limited to centrifugation through a cesium chloride gradient, including the method as described by Chirgwin, J. M., et al., *Biochemistry* 18:5294-5299, (1979), and co-precipitation of extracellular RNA from plasma or serum with gelatin, such as by adaptations of the method of Fournie, G. J., et al., *Analytical Biochemistry* 158:250-256, (1986), to RNA extraction.

Alternative Nucleic Acid Amplification Methods

[0063] Alternative methods of nucleic acid amplification which may be used include variations of RT-PCR, including quantitative RT-PCR, for example as adapted to the method described by Wang, A. M. et al., *Proc. Natl. Acad. Sci. USA* 86:9717-9721, (1989), or by Karet, F. E., et al., *Analytical Biochemistry* 220:384-390, (1994). Another method of nucleic acid amplification or mutation detection which may be used is ligase chain reaction (LCR), as described by Wiedmann, et al., *PCR Methods Appl.* 3:551-564, (1994). An alternative method of amplification or mutation detection is allele specific PCR (ASPCR). ASPCR which utilizes matching or mismatching between the template and the 3' end base of a primer

well known in the art. See e.g., U.S. Patent 5,639,611.

[0064] Another method of mutation detection is nucleic acid sequencing. Sequencing can be performed using any number of methods, kits or systems known in the art. One example is using dye terminator chemistry and an ABI sequencer (Applied Biosystems, Foster City, CA). Sequencing also may involve single base determination methods such as single nucleotide primer extension ("SNaPshot®" sequencing method) or allele or mutation specific PCR. The SNaPshot® Multiplex System is a primer extension-based method that enables multiplexing up to 10 SNPs (single nucleotide polymorphisms). The chemistry is based on the dideoxy single-base extension of an unlabeled oligonucleotide primer (or primers). Each primer binds to a complementary template in the presence of fluorescently labeled ddNTPs and AmpliTaq® DNA Polymerase, FS. The polymerase extends the primer by one nucleotide, adding a single ddNTP to its 3' end. SNaPshot® Multiplex System is commercially available (ABI PRISM® SNaPshot® Multiplex kit, Applied Biosystems Foster City, CA). Products generated using the ABI PRISM® SNaPshot® Multiplex kit can be analyzed with GeneScan® Analysis Software version 3.1 or higher using ABI PRISM®310 Genetic Analyzer, ABI PRISM® 3100 Genetic Analyzer or ABI PRISM® 3700 DNA Analyzer.

Exemplary Methods for Detection of JAK2 DNA and RNA Mutations

[0065] Nucleic acid (e.g., total nucleic acid) may be extracted from patient's biological sample using any appropriate method. Next, an RT-PCR reaction may be performed using either the total nucleic acid preparation or the RNA preparation to specifically amplify a portion of the patient RNA. An exemplary one-step RT-PCR system is the Superscript III System (Invitrogen, Carlsbad, CA). Other methods and systems for RT-PCR reactions are well known in the art and are commercially available. By way of example, but not by way of limitation, a primer pair for JAK2 may be 5'-TGT AAA ACG ACG GCC AGT CTA AAT GCT GTC CCC CAA AG-3' (forward primer, SEQ ID NO: 6) and 5'-CAG GAA ACA GCT ATG ACC CCA TGC CAA CTG TTT AGC AA-3' (reverse primer, SEQ ID NO: 7). The RT-PCR product may then be purified, for example by gel purification, and the resulting purified product may be sequenced. Nucleic acid sequencing methods are known in the art; an exemplary sequencing method includes the ABI Prism BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA). The sequencing data may then be analyzed for the presence or absence of one or more mutations in JAK2 nucleic acid. The sequencing data may also be analyzed to determine the proportion of wild-type to mutant nucleic acid present in the sample.

[0066] The presence or absence of JAK2 mutations can be determined in a nucleic acid by sequencing appropriate portions of the JAK2 gene containing the mutations sought to be detected. For example, each amplicon of the JAK2 gene is sequenced with forward and reverse primers. In another approach, JAK2 mutations that change susceptibility to digestion by one or more endonuclease restriction enzymes may be used to detect the mutations. In another embodiment, the presence of one or more JAK2 mutations can be determined by allele specific amplification. In yet another embodiment, the presence of one or more JAK2 mutations can be determined by primer extension. In yet a further embodiment, the presence of one or more JAK2 mutations can be determined by oligonucleotide ligation. In another embodiment, the presence of one or more JAK2 mutations can be determined by hybridization with a detectably labeled probe containing the mutant JAK2 sequence. The presence or absence of JAK2 mutations can be determined by any known or future method.

Detection of Mutated JAK2 Proteins

[0067] According to the invention, the presence or absence of JAK2 mutations can also be determined by analyzing the JAK2 protein (SEQ ID NO: 2) encoded by the mutated JAK2 gene. The mutations include those shown in Table 2. Detection of JAK2 mutations at the protein level can be detected by any method well known in the field. In one embodiment, detection of JAK2 mutations is carried out by isolating JAK2 protein and subjecting it to amino acid sequence determination. This may require fragmenting the protein by proteolytic or chemical means prior to sequencing. Methods of determining an amino acid sequence are well known in the art.

[0068] Detection of mutated JAK2 proteins can be accomplished using, for example, antibodies, aptamers, ligands/substrates, other proteins or protein fragments, other protein-binding agents, or mass spectrometry analysis of fragments. Preferably, protein detection agents are specific for the mutated JAK2 protein of the present invention and can therefore discriminate between a mutated protein and the wild-type protein or another variant form. This can generally be accomplished by, for example, selecting or designing detection agents that bind to the region of a protein that differs between the variant and wild-type protein.

[0069] One preferred agent for detecting a mutated JAK2 protein is an antibody capable of selectively binding to a variant form of the protein. Antibodies capable of distinguishing between wild-type and mutated JAK2 protein may be created by any suitable method known in the art. The antibodies may be monoclonal or polyclonal antibodies, single chain or double chain, chimeric or humanized antibodies or portions of immunoglobulin molecules containing the portions known in the state of the art to correspond to the antigen binding fragments.

[0070] Methods for manufacturing polyclonal antibodies are well known in the art. Typically, antibodies are created by administering (e.g., via subcutaneous injection) the mutated JAK2 protein immunogenic fragment containing the mutation to white New Zealand rabbits. The JAK2 antigen is typically injected at multiple sites and the injections are repeated multiple times (e.g., approximately bi-weekly) to induce an immune response. Desirably, the rabbits are simultaneously administered an adjuvant to enhance anti-JAK2 immunity. The polyclonal antibodies are then purified from a serum sample, for example, by affinity chromatography using the same JAK2 antigen to capture the antibodies. The antibodies can be made specific to the mutation by removing antibodies cross-reacting with native JAK2.

[0071] In vitro methods for detection of the mutated JAK2 proteins also include, for example, enzyme linked immunosorbent assays (ELISAs), radioimmunoassays (RIA), Western blots, immunoprecipitations, immunofluorescence, and protein arrays/chips (e.g., arrays of antibodies or aptamers). For further information regarding immunoassays and related protein detection methods, see Current Protocols in Immunology, John Wiley & Sons, N.Y., and Hage, "Immunoassays", Anal Chem. 1999 Jun. 15; 71(12):294R-304R. Additional analytic methods of detecting amino acid variants include, but are not limited to, altered electrophoretic mobility (e.g., 2-dimensional electrophoresis), altered tryptic peptide digest, altered JAK2 kinase activity in cell-based or cell-free assay, alteration in ligand or antibody-binding pattern, altered isoelectric point, and direct amino acid sequencing.

Diagnostic Tools

[0072] JAK2 nucleic acid may be used as tools to diagnose an individual as having (or as likely to develop) a myeloproliferative disease. Alternatively, the JAK2 mutation status, used alone or in combination with other clinical parameters, also may be used to determine a prognosis for a patient diagnosed as having a myeloproliferative disease. Exemplary mutations in JAK2 nucleic acid is listed in Tables 1 and 2.

[0073] In some embodiments, the JAK2 nucleic acids further comprise a detectable label and are used as a probe ("JAK2 probe") to detect mutated JAK2 nucleic acids in a patient sample. The JAK2 probe may be detectably labeled by methods known in the art. Useful labels include, for example, fluorescent dyes (e.g., Cy5®, Cy3®, FITC, rhodamine, lanthamide phosphors, Texas red, FAM, JOE, Cal Fluor Red 610®, Quasar 670®), radioisotopes (e.g., ³²P, ³⁵S, ³H, ¹⁴C, ¹²⁵I, ¹³¹I), electron-dense reagents (e.g., gold), enzymes (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase), colorimetric labels (e.g., colloidal gold), magnetic labels (e.g., Dynabeads™), biotin, dioxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available. Other labels include ligands or oligonucleotides capable of forming a complex with the corresponding receptor or oligonucleotide complement, respectively. The label can be directly incorporated into the nucleic acid to be detected, or it can be attached to a probe (e.g., an oligonucleotide) or antibody that hybridizes or binds to the nucleic acid to be detected.

[0074] In other embodiments, the JAK2 probes are TaqMan® probes, molecular beacons, and Scorpions (e.g., Scorpion™ probes). These types of probes are based on the principle of fluorescence quenching and involve a donor fluorophore and a quenching moiety. The term "fluorophore" as used herein refers to a molecule that absorbs light at a particular wavelength (excitation frequency) and subsequently emits light of a longer wavelength (emission frequency). The term "donor fluorophore" as used herein means a fluorophore that, when in close proximity to a quencher moiety, donates or transfers emission energy to the quencher. As a result of donating energy to the quencher moiety, the donor fluorophore will itself emit less light at a particular emission frequency that it would have in the absence of a closely positioned quencher moiety.

[0075] The term "quencher moiety" as used herein means a molecule that, in close proximity to a donor fluorophore, takes up emission energy generated by the donor and either dissipates the energy as heat or emits light of a longer wavelength than the emission wavelength of the donor. In the latter case, the quencher is considered to be an acceptor fluorophore. The quenching moiety can act via proximal (i.e., collisional) quenching or by Förster or fluorescence resonance energy transfer ("FRET"). Quenching by FRET is generally used in TaqMan® probes while proximal quenching is used in molecular beacon and Scorpion™ type probes. Suitable quenchers are selected based on the fluorescence spectrum of the particular fluorophore. Useful quenchers include, for example, the Black Hole™ quenchers BHQ-1, BHQ-2, and BHQ-3 (Biosearch Technologies, Inc.), and the ATTO-series of quenchers (ATTO 540Q, ATTO 580Q, and ATTO 612Q; Atto-Tec GmbH).

[0076] With Scorpion primers, sequence-specific priming and PCR product detection is achieved using a single molecule. The Scorpion primer maintains a stem-loop configuration in the unhybridized state. The fluorophore is attached to the 5' end and is quenched by a moiety coupled to the 3' end, although in suitable embodiments, this arrangement may be switched. The 3' portion of the stem also contains sequence that is complementary to the extension product of the primer. This sequence is linked to the 5' end of a specific primer via a non-amplifiable monomer. After extension of the primer moiety, the specific probe sequence is able to bind to its complement within the extended amplicon thus opening up the hairpin loop. This prevents the fluorescence from being quenched and a signal is observed. A specific target is amplified by the reverse primer and the primer portion of the Scorpion primer, resulting in an extension product. A fluorescent signal is generated due to the separation of the fluorophore from the quencher resulting from the binding

of the probe element (e.g., the JAK2 probe) of the Scorpion primer to the extension product.

[0077] TaqMan® probes (Heid, et al., Genome Res 6: 986-994, 1996) use the fluorogenic 5' exonuclease activity of Taq polymerase to measure the amount of target sequences in cDNA samples. TaqMan® probes are oligonucleotides that contain a donor fluorophore usually at or near the 5' base, and a quenching moiety typically at or near the 3' base. The quencher moiety may be a dye such as TAMRA or may be a non-fluorescent molecule such as 4-(4-dimethylaminophenylazo) benzoic acid (DABCYL). See Tyagi, et al., 16 Nature Biotechnology 49-53 (1998). When irradiated, the excited fluorescent donor transfers energy to the nearby quenching moiety by FRET rather than fluorescing. Thus, the close proximity of the donor and quencher prevents emission of donor fluorescence while the probe is intact.

[0078] TaqMan® probes are designed to anneal to an internal region of a PCR product. When the polymerase (e.g., reverse transcriptase) replicates a template on which a TaqMan® probe is bound, its 5' exonuclease activity cleaves the probe. This ends the activity of the quencher (no FRET) and the donor fluorophore starts to emit fluorescence which increases in each cycle proportional to the rate of probe cleavage. Accumulation of PCR product is detected by monitoring the increase in fluorescence of the reporter dye (note that primers are not labeled). If the quencher is an acceptor fluorophore, then accumulation of PCR product can be detected by monitoring the decrease in fluorescence of the acceptor fluorophore.

[0079] The JAK2 polypeptides of this invention include, for example, polypeptides that are substantially identical to a portion of the JAK2 amino acid sequence of SEQ ID NO: 2 and further comprise one or more of the following mutations listed in Table 2. These polypeptides may be used as tools to diagnose an individual as having (or as likely to develop) a myeloproliferative disease. Alternatively, the JAK2 mutation status, used alone or in combination with other clinical parameters, also may be used to determine a prognosis for a patient diagnosed as having a myeloproliferative disease. In some embodiments, the JAK2 polypeptides have at least 10, 12, 14, 16, 18, 20, 25, 30, 40, 50, 75, 100, or more amino acids. In some embodiments, the JAK2 polypeptide is less than 1100, 1000, 900, 800, 700, 600, 500, or 400 amino acids.

Kits For Detecting JAK2 Mutations

[0080] Also disclosed are kits for detecting JAK2 mutations. The kits can contain at least a primer pair capable of amplifying a target JAK2 nucleic acid sequence of SEQ ID NO: 1 and a means for detecting a JAK2 mutation in the target. Preferably, the amplification using the primer pair of the kit results in a reaction product having at least 20, 40, 60, 80, 100, 125, 150, 200, 300, 500, or more nucleotides. Suitable primer pairs include, for example, primers having the sequence of SEQ ID NOs: 6 and 7. Suitable means for detecting a JAK2 mutation in the reaction product make use of a detectably labeled JAK2 probe, such as those described herein.

Diagnosis, Detection, and Prognosis

[0081] The presence of the JAK2 mutations, such as, for example, the mutations listed in Table 2 alone, in combination with each other, or in combination with other JAK2 mutations can be as an indicator of disease.

[0082] Without wishing to be bound by any theory, it is believed that the JAK2 mutations allow the activation loop of the kinase domain to move away from the pseudokinase domain, thus leading to constitutive activation of the JAK2-STAT pathway. Mutations in the pseudokinase domain are expected to inactivate the auto-inhibitory function of the pseudokinase domain on the kinase activity. A considerable portion of activating mutations in tyrosine kinases associated with human cancer are loss-of-function alleles residing in the auto-inhibitory domains, for example, point mutations and deletions that result in constitutive tyrosine kinase activation. Therefore, testing for JAK2 mutations should include most of the pseudokinase domain.

[0083] Without wishing to be bound by any theory, it has been suggested from homology modeling approaches that residues 537 through 543 (mutation hot spots in exon 12) lie within a loop region bridging the SH2 and JH2 domains of JAK2. In the predicted model, positive polar or hydrophobic interactions between D407-K655, S411-E653, K415-E685 and F408-H608 from the SH2 and the JH2 domains, respectively, are closely packed in the predicted interface that further supported the JH2-JH1 interaction (21). Therefore, mutations in this loop area may disrupt JH2-JH1 interaction leading to constitutive kinase activation, e.g., del/F537-K539ins/L, del/N542-E543, H538QK539L and K539L, all displayed increased JAK2 activation, cytokine-independent hypersensitive proliferation, and in the case of K539L, developed a myeloproliferative phenotype. See e.g., Scott et al., N Engl J Med 356:459-468 (2007).

[0084] One or more of the following determinations may be used to diagnose a patient: determining the presence or absence of a specific JAK2 mutation, determining the zygosity status of the sample, and determining the ratio of mutant to wild-type JAK2 nucleic acid or mRNA in the sample. For example, patients found to carry a specific JAK2 mutation by the methods of the invention may be recommended for further testing to verify an MPD diagnosis, or detection of the mutation may be used to finally confirm a preliminary diagnosis of MPD (e.g., if a patient is symptomatic for an MPD and also tests positive for a specific JAK2 mutation known to be indicative of a particular MPD, the patient may be finally

diagnosed with an MPD such as PV). Similarly, methods of the invention may be used to diagnose patients who are asymptomatic for MPD, for example patients who are in the very early stages of an MPD. JAK2 mutations may also be detected in MPD patients who are undergoing treatment; if the ratio of mutant to wild-type JAK2 nucleic acid or the zygosity status of the sample changes during treatment, a different diagnosis may be made.

5 **[0085]** One or more of the following determinations may be used to treat a patient: determining the presence or absence of a specific JAK2 mutation, determining the zygosity status of the sample, and determining the ratio of mutant to wild-type JAK2 nucleic acid in a sample. A physician or treatment specialist may administer, forego or alter a treatment or treatment regime based on one or more of the determinations. Further, the number of cancerous cells carrying the mutation may change during the course of an MPD and monitoring the ratio, the zygosity status, and/or the presence or absence of a JAK2 mutation may be an indication of disease status or treatment efficacy. For example, treatment may reduce the number of mutant cancerous cells, or the disease may become worse with time, and the number of diseased cells may increase. Additionally, one or more of the determinations may aid in patient prognosis and quality of life decisions. For example, decisions about whether to continue - or for how long to continue - a painful, debilitating treatment such as chemotherapy may be made.

10 **[0086]** The zygosity status and the ratio of wild-type to mutant nucleic acid in a sample may be determined by methods known in the art including sequence-specific, quantitative detection methods. Other methods may involve determining the area under the curves of the sequencing peaks from standard sequencing electropherograms, such as those created using ABI Sequencing Systems, (Applied Biosystems, Foster City CA). For example, the presence of only a single peak such as a "G" on an electropherogram in a position representative of a particular nucleotide is an indication that the nucleic acids in the sample contain only one nucleotide at that position, the "G." The sample may then be categorized as homozygous because only one allele is detected. The presence of two peaks, for example, a "G" peak and a "T" peak in the same position on the electropherogram indicates that the sample contains two species of nucleic acids; one species carries the "G" at the nucleotide position in question, the other carries the "T" at the nucleotide position in question. The sample may then be categorized as heterozygous because more than one allele is detected.

15 **[0087]** The sizes of the two peaks may be determined (e.g., by determining the area under each curve), and a ratio of the two different nucleic acid species may be calculated. A ratio of wild-type to mutant nucleic acid may be used to monitor disease progression, determine treatment, or to make a diagnosis. For example, the number of cancerous cells carrying a specific JAK2 mutation may change during the course of an MPD. If a base line ratio is established early in the disease, a later determined higher ratio of mutant nucleic acid relative to wild-type nucleic acid may be an indication that the disease is becoming worse or a treatment is ineffective; the number of cells carrying the mutation may be increasing in the patient. A lower ratio of mutant relative to wild-type nucleic acid may be an indication that a treatment is working or that the disease is not progressing; the number of cells carrying the mutation may be decreasing in the patient.

35 EXAMPLES

EXAMPLE 1: Detection of the JAK2 Mutations

40 **[0088]** Approximately 20,000 patient samples with suspicious diagnosis of MPD over a period of 7 months (from November, 2007 through June, 2008) were collected and screened for *JAK2* gene mutation through the region of entire exons 12-15. Five milliliters of blood in Lavender (purple top tubes) containing ethylenediaminetetraacetic acid (EDTA) anticoagulant were required for analysis. Blood samples were refrigerated (not frozen) or kept at room temperature no more than 48 hr if immediate nucleic acid extraction was not possible.

45 **[0089]** Total nucleic acids were isolated from peripheral blood plasma by the NucliSens extraction kit (bioMerieux Inc., Durham, NC, USA) according to the manufacturer's instructions. First strand cDNAs were then prepared by reverse transcription of total RNAs with random primers at 55°C for 30 min, followed by PCR reactions using SuperSript III one-step RT-PCR system with Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA). For amplification of the *JAK2* exons 12-15, the following primer set and conditions were used: 5'-TGT AAA ACG ACG GCC AGT CTA AAT GCT GTC CCC CAA AG-3' (forward primer, SEQ ID NO: 6) and 5'-CAG GAA ACA GCT ATG ACC CCA TGC CAA CTG TTT AGC AA-3' (reverse primer, SEQ ID NO: 7); initial step of 2 min at 94 °C, followed by 40 cycles of 94 °C for 15 sec, 60 °C for 30 sec, and 68 °C for 1 min, and ending with one step of 68 °C for 7 min. The 491-bp amplified products were filter-purified by Multiscreen PCR plates (Millipore, Billerica, MA, USA) and sequenced in both directions using the ABI Prism BigDye® Terminator v3.1 Cycle Sequencing Kit and detected by ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Sequence data was then base-called, assembled and analyzed by ABI Prism® SeqScape software (Applied Biosystems, Foster City, CA, USA) using the *JAK2* sequence (accession number NM004972) as a reference.

50 **[0090]** Table 1 presents a mutation analysis of *JAK2* gene exon 12 (SEQ ID NO: 3), exon 13 (SEQ ID NO: 4), exon 14 (SEQ ID NO: 5), and exon 15 from a large group of suspected MPD blood samples.

EP 2 770 066 B1

Table 1: Mutation Analysis

	Exon*	Mutation	Codon change	No. of cases	Pattern on sequencing#
5	12	Silent	H531	1	Heterozygous
	12	Duplication	dupl/V536-F547	2	Heterozygous
	12	Deletion	del H538	1	Heterozygous
	12	Deletion	del/H538-K539	1	Heterozygous
	12	Deletion	del/N542-E543	5	Heterozygous
10	12	Deletion	del/E543-D544	3	Heterozygous
			del/F537-K539	1	
15	12	Indels	ins/K		Heterozygous
			del/F537-K539	2	
	12	Indels	ins/L		Heterozygous
	12	Indels	del/H538-K539	4	Heterozygous
20	12	Indels	ins/L		Heterozygous
	12	Indels	del/R541-E543	1	Heterozygous
	12	Indels	ins/K		Heterozygous
25	12	Indels	del/I540-D544	1	Heterozygous
	12	Indels	ins/MK		Heterozygous
	12	Indels	del/N542-D544	1	Heterozygous
	12	Indels	ins/N		Heterozygous
	12	Missense	T514M	2	Heterozygous
30	12	Missense	N533Y	1	Heterozygous
	12	Missense	K539L	2	Heterozygous
	12	Missense	H538Q	1	Heterozygous
	12	Missense	K539L		Heterozygous
35	12	Missense	K539L	1	Heterozygous
	12	Missense	L545V		Heterozygous
	12	Missense	F547L	1	Heterozygous
	13	Silent	G562	2	Heterozygous
	13	Silent	Y570	4	Heterozygous
	13	Silent	F556	1	Heterozygous
	13	Missense	R564L	3	Heterozygous
	13	Missense	R564Q	2	Heterozygous
	13	Missense	V567A	1	Heterozygous
	13	Missense	G571S	3	Heterozygous
40	13	Missense	G571R	1	Heterozygous
	13	Missense	L579F	1	Heterozygous
	13	Missense	H587N	1	Heterozygous
	13	Missense	S591L	1	Heterozygous
	13	Missense	S593-N622	1	Heterozygous
	14	Deletion	S593-N622	2	Heterozygous
	14	Missense	H606Q	1	Heterozygous
45	14	Missense	V617F	>2000	Hetero/Homo
	14	Missense	V617I	1	Heterozygous
	14	Missense	V617F		Heterozygous
	14	Missense			Hetero/Homo
50	14	Missense	C618R	2	Hetero/Homo
	14	Missense	C618R	1	Heterozygous
	15	Missense	L624P	1	Heterozygous
55	15	Missense	I645V	1	Heterozygous

*Exon 12 (residues 511-547); Exon13 (residues 548-592); Exon14 (residues 593-622).

EP 2 770 066 B1

EXAMPLE 2: Additional JAK2 Mutations

[0091] Table 2 presents additional specific examples of novel JAK2 mutations identified by sequencing, along with their deduced amino acid substitutions.

Table 2: Exons 12, 13, 14, and 15 Mutations

Exon 12	
JAK2 Mutation Nucleic Acid; (Codon Change)	JAK2 Mutation Protein; (Amino Acid Change)
Missense Mutations	
c2035t; (acg>atg)	T514M; (Thr → Met)
a2091t ; (aac>tac)	N533Y (Asn → Tyr)
t2127c; (ttg>gtg)	L545V; (Leu → Val)
t2133c; (ttt>ctt)	F547L; (Phe → Leu)
del: deletion; ins: insertion	
Exon 13	
JAK2 Mutation Nucleic Acid; (Codon Change)	JAK2 Mutation Protein; (Amino Acid Change)
Missense Mutations	
t2160g ttt>gtt	F556V (Phe → Val)
c2180t; (ggc>ggt)	G562 silent; (Gly)
g2185t; (cga>cta)	R564L; (Arg → Leu)
g2185a; (cga>caa)	R564Q; (Arg → Gln)
g2193t; (gta>tta)	V567L; (Val → Leu)
t2194c; (gta>gca)	V567A; (Val → Ala)
c2204t; (tac>tat)	Y570 Silent; (Tyr)
g2205a; (ggg>agt)	G571S; (Gly → Ser)
g2205c; (ggg>cgt)	G571R; (Gly → Arg)
c2229t; (ctt>ttt)	L579F; (Leu → Phe)
c2253a; (cac>aac)	H587N; (His → Asn)
c2266t; (tca>tta)	S591L; (Ser → Leu)
Exon 14	
JAK2 Mutation Nucleic Acid; (Codon Change)	JAK2 Mutation Protein; (Amino Acid Change)
Exon 14 Missense and Deletion Mutations	
c2312a; (cac>caa)	H606Q; (His → Gln)
2271-2358 (exon 14 deletion)	S593-N622
Exon 15	
Exon 15 Missense Mutations	
t2365c; (ctg>ccg)	L624P; (Leu → Pro)
a2427g; (ata>gta)	I645V; (Ile → Val)

[0092] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0093] The inventions illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising," "including,"

"containing," etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.

5 [0094] Thus, it should be understood that although the invention has been specifically disclosed by preferred embodiments and optional features, modification, improvement and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications, improvements and variations are considered to be within the scope of this invention. The materials, methods, and examples provided here are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention.

10 [0095] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

15 [0096] In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0097] Further disclosed are the following items:

20 Item 1: An isolated nucleic acid comprising at least 17 contiguous nucleotides corresponding to SEQ ID NO: 1, wherein said nucleic acid comprises a mutation selected from the group consisting of the mutations shown in Table 2, and wherein said nucleic acid is less than 5000 nucleotides in length.

25 Item 2: The isolated nucleic acid of claim 1, wherein said nucleic acid further comprises at least one additional mutation shown in Table 2.

Item 3: The isolated nucleic acid of any one of claims 1-2, wherein said nucleic acid is labeled with a detectable label.

30 Item 4: A polypeptide comprising at least 10 contiguous amino acids corresponding to SEQ ID NO: 2, wherein said polypeptide comprises a mutation selected from the group consisting of the mutations shown in Table 2, and wherein said polypeptide is less than 1100 amino acids.

Item 5: The polypeptide of claim 4, wherein said polypeptide further comprises at least one additional mutation shown in Table 2.

35 Item 6: The polypeptide of any one of claims 4-5, wherein said polypeptide is labeled with a detectable label

Item 7: A method for diagnosing a hematopoietic disease in an individual comprising:

40 a) providing sample from said individual, wherein said sample comprises JAK2 nucleic acid;

b) evaluating a sample containing nucleic acids from the individual for the presence or absence of one or more mutations in JAK2 nucleic acid, wherein said one or more mutations is selected from the group consisting of the mutations of Table 2; and

45 c) identifying said individual as having a hematopoietic disease when said JAK2 nucleic acid comprises at least one of said mutations.

Item 8: The method of item 7, wherein the JAK2 nucleic acid is RNA.

50 Item 9: The method of any one of items 7-8, wherein said sample is selected from the group consisting of blood, serum, and plasma.

Item 10: The method of any one of items 7-9, wherein said JAK2 nucleic acid further comprises at least one additional mutation shown in Table 2.

55 Item 11: The method of any one of items 7-10, wherein said hematopoietic disease is a myeloproliferative disease.

Item 12: The method of item 11, wherein said myeloproliferative disease is selected from the group consisting of

polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, and unclassified myeloproliferative disease.

Item 13: The method of any one of item 7-12, wherein said evaluating step comprises amplifying JAK2 nucleic acid and hybridizing the amplified nucleic acid with a detection oligonucleotide that is capable of specifically detecting JAK2 nucleic acid under hybridization conditions.

Item 14: The method of any one of items 7-13, wherein said evaluating step comprises amplifying JAK2 nucleic acid and performing direct sequencing analysis of the amplified nucleic acid.

Item 15: A method of determining a prognosis of an individual diagnosed with a hematopoietic disease, said method comprising:

(a) determining the presence or absence of one or more mutations in a JAK2 nucleic acid sample, wherein said one or more mutations is selected from the group consisting of the mutations of Table 2; and

(b) identifying said individual as having poor prognosis when one or more mutations are present in a JAK2 nucleic acid sample.

Item 16: A method for diagnosing a hematopoietic disease in an individual comprising:

a) evaluating a sample from the individual for the presence or absence of one or more mutations in JAK2 polypeptide, wherein said one or more mutations is selected from the group consisting of the mutations of Table 2, and

b) identifying said individual as having hematopoietic disease when at least one of said mutation in JAK2 polypeptide is present.

Item 17: The method of any one of items 15-16, wherein said sample is selected from the group consisting of blood, serum, and plasma.

Item 18: The method of any one of items 15-17, wherein said JAK2 polypeptide further comprises at least one additional mutation shown in Table 2.

Item 19: The method of any one of items 15-18, wherein said hematopoietic disease is a myeloproliferative disease.

Item 20: The method of item 19, wherein said myeloproliferative disease is selected from the group consisting of polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, and unclassified myeloproliferative disease.

Item 21: The method of any one of items 15-20, wherein said evaluating step comprises using an antibody that specifically binds to the mutated JAK2 polypeptide.

Item 22: A method for determining a prognosis of an individual diagnosed with a hematopoietic disease, said method comprising:

(a) determining the presence or absence of one or more mutations in a JAK2 polypeptide sample, wherein said one or more mutations is selected from the group consisting of the mutations of Table 2; and

(b) identifying said individual as having poor prognosis when one or more mutations in a JAK2 polypeptide is present.

SEQUENCE LISTING

[0098]

<110> ALBITAR, MAHER MA, WANLONG

<120> COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID

EP 2 770 066 B1

<130> 034827-0651

<140> 12/503,318

<141> 2009-07-15

5

<150> 61/110,501

<151> 2008-10-31

<160> 11

10

<170> PatentIn version 3.5

<210> 1

<211> 5097

15

<212> DNA

<213> Homo sapiens

<400> 1

20

ctgcaggaag gagagaggaa gaggagcaga agggggcagc agcggacgcc gctaacggcc 60

tccctcggcg ctgacaggct gggccggcgc ccggctcgc tgggtgttcg cgtcggcact 120

25

tcggcttctc ggccggtcgg gccctcggc ccgggcttgc ggcgcgcgtc ggggctgagg 180

gctgctgcgg cgcagggaga ggcctggtcc tcgctgccga gggatgtgag tgggagctga 240

gcccacactg gagggccccc gagggcccag cctggaggtc gttcagagcc gtgcccggcc 300

30

cggggcttcg cagacctga cccgccgggt aggagccgcc cctgcgggct cgagggcgcg 360

ctctggctgc ccgatctgtg tagccggtt cagaagcagg caacaggaac aagatgtgaa 420

ctgtttctct tctgcagaaa aagaggctct tcctcctcct cccgcgacgg caaatgttct 480

35

gaaaaagact ctgcatggga atggcctgcc ttacgatgac agaaatggag ggaacatcca 540

cctcttctat atatcagaat ggtgatattt ctggaaatgc caattctatg aagcaaatag 600

atccagttct tcaggtgat ctttaccatt cccttgggaa atctgaggca gattatctga 660

40

cctttccatc tggggagtat gttgcagaag aaatctgtat tgctgcttct aaagcttgtg 720

gtatcacacc tgtgtatcat aatatgtttg cttaaatgag tgaaacagaa aggatctggt 780

45

atccacccaa ccatgtcttc catatagatg agtcaaccag gcataatgta ctctacagaa 840

taagatttta ctttcctcgt tggatttgca gtggcagcaa cagagcctat cggcatggaa 900

tatctcgagg tgctgaagct cctcttcttg atgactttgt catgtcttac ctctttgctc 960

50

agtggcggca tgattttgtg cacggatgga taaaagtacc tgtgactcat gaaacacagg 1020

aagaatgtct tgggatggca gtgttagata tgatgagaat agccaaagaa aacgatcaaa 1080

55

ccccactggc catctataac tctatcagct acaagacatt cttaccaaaa tgtattcgag 1140

EP 2 770 066 B1

caaagatcca agactatcat attttgacaa ggaagcgaat aaggtacaga tttcgcagat 1200
 ttattcagca attcagccaa tgcaaagcca ctgccagaaa cttgaaactt aagtatctta 1260
 5 taaatctgga aactctgcag tctgccttct acacagagaa atttgaagta aaagaacctg 1320
 gaagtgggtcc ttcaggtgag gagatTTTTG caaccattat aataactgga aacggtggaa 1380
 ttcagtggtc aagagggaaa cataaagaaa gtgagacact gacagaacag gatttacagt 1440
 10 tatattgcca ttttcctaatt attattgatg tcagtattaa gcaagcaaac caagagggtt 1500
 caaatgaaag ccgagttgta actatccata agcaagatgg taaaaatctg gaaattgaac 1560
 ttagctcatt aaggaagct ttgtctttcg tgtcattaat tgatggatat tatagattaa 1620
 15 ctgcagatgc acatcattac ctctgtaaag aagtagcacc tccagccgtg cttgaaaata 1680
 taciaagcaa ctgtcatggc ccaatttcga tggatTTTTG cattagtaaa ctgaagaaag 1740
 caggtaatca gactggactg tatgtacttc gatgcagtc taaggacttt aataaatatt 1800
 20 ttttgacttt tgctgtcgag cgagaaaatg tcattgaata taaacactgt ttgattacaa 1860
 aaaatgagaa tgaagagtac aacctcagtg ggacaaagaa gaacttcagc agtcttaaag 1920
 25 atcttttgaa ttgttaccag atggaaactg ttcgctcaga caatataatt ttccagttta 1980
 ctaaagtctg tcccccaaag ccaaagata aatcaaacct tctagtcttc agaacgaatg 2040
 gtgtttctga tgtaccaacc tcaccaacat tacagaggcc tactcatatg aaccaaattg 2100
 30 tgtttcacaa aatcagaaat gaagatttga tatttaatga aagccttggc caaggcactt 2160
 ttaciaaagat ttttaaaggc gtacgaagag aagtaggaga ctacggtcaa ctgcatgaaa 2220
 cagaagttct tttaaaagtt ctggataaag cacacagaaa ctattcagag tctttctttg 2280
 35 aagcagcaag tatgatgagc aagctttctc acaagcattt ggttttaaat tatggagtat 2340
 gtgtctgtgg agacgagaat attctggttc aggagtttgt aaaatttggg tctactagata 2400
 40 catatctgaa aaagaataaa aattgtataa atatattatg gaaacttgaa gttgctaaac 2460
 agttggcatg ggccatgcat tttctagaag aaaacaccct tattcatggg aatgtatgtg 2520
 ccaaaaatat tctgcttatc agagaagaag acaggaagac aggaaatcct ctttcatca 2580
 45 aacttagtga tcctggcatt agtattacag ttttgccaaa ggacattctt caggagagaa 2640
 taccatgggt accacctgaa tgcattgaaa atcctaaaaa tttaaatttg gcaacagaca 2700
 aatggagttt tggtagcact ttgtgggaaa tctgcagtgaggaggataaaa cctctaagtg 2760
 50 ctctggattc tcaaagaaag ctacaatttt atgaagatag gcatcagctt cctgcaccaa 2820
 agtgggcaga attagcaaac cttataaata attgtatgga ttatgaacca gatttcaggc 2880
 cttctttcag agccatcata cgagatctta acagtttgtt tactccagat tatgaactat 2940
 55 taacagaaaa tgacatgtta ccaaataatga ggataggtgc cctagggttt tctggtgcct 3000

EP 2 770 066 B1

	ttgaagaccg	ggatcctaca	cagtttgaag	agagacattt	gaaatttcta	cagcaacttg	3060
	gcaagggtaa	ttttgggagt	gtggagatgt	gccggtatga	ccctctacag	gacaacactg	3120
5	gggaggtggt	cgctgtaaaa	aagcttcagc	atagtactga	agagcaccta	agagactttg	3180
	aaagggaaat	tgaaatcctg	aaatccctac	agcatgacaa	cattgtaaag	tacaagggag	3240
	tgtgctacag	tgctggtcgg	cgtaatctaa	aattaattat	ggaatattta	ccatattgaa	3300
10	gtttacgaga	ctatcttcaa	aaacataaag	aacggataga	tcacataaaa	cttctgcagt	3360
	acacatctca	gatatgcaag	ggatggagt	atcttggtag	aaaaggtat	atccacaggg	3420
	atctggcaac	gagaaatata	ttggtggaga	acgagaacag	agttaaaatt	ggagattttg	3480
15	ggttaaccaa	agtcttgcca	caagacaaaag	aatactataa	agtaaaagaa	cctggtgaaa	3540
	gtcccatatt	ctggtatgct	ccagaatcac	tgacagagag	caagttttct	gtggcctcag	3600
	atgtttggag	ctttggagtg	gttctgtatg	aacttttcac	atacattgag	aagagtaaaa	3660
20	gtccaccagc	ggaatztatg	cgtatgattg	gcaatgacaa	acaaggacag	atgatcgtgt	3720
	tccatttgat	agaacttttg	aagaataatg	gaagattacc	aagaccagat	ggatgccag	3780
	atgagatcta	tatgatcatg	acagaatgct	ggaacaataa	tgtaaatcaa	cgcccctcct	3840
25	ttagggatct	agctcttcga	gtggatcaaa	taagggataa	catggctgga	tgaaagaaat	3900
	gaccttcatt	ctgagaccaa	agtagattta	cagaacaaaag	ttttatattt	cacattgctg	3960
	tggtactatta	ttacatatat	cattattata	taaatcatga	tgctagccag	caaagatgtg	4020
30	aaaatatctg	ctcaaaaactt	tcaaagttta	gtaagttttt	cttcatgagg	ccaccagtaa	4080
	aagacattaa	tgagaattcc	ttagcaagga	ttttgtaaga	agtttcttaa	acattgtctg	4140
35	ttaacatcac	tcttgtctgg	caaaagaaaa	aaaatagact	ttttcaactc	agctttttga	4200
	gacctgaaaa	aattattatg	taaattttgc	aatgttaaag	atgcacagaa	tatgtatgta	4260
	tagtttttac	cacagtggat	gtataatacc	ttggcatctt	gtgtgatggt	ttacacacat	4320
40	gagggctggt	gttcattaat	actgttttct	aatttttcca	tagttaatct	ataattaatt	4380
	acttcactat	acaaacaaat	taagatgttc	agataattga	ataagtacct	ttgtgtcctt	4440
	gttcatttat	atcgctggcc	agcattataa	gcaggtgtat	acttttagct	tgtagttcca	4500
45	tgtactgtaa	atatttttca	cataaagggg	acaaatgtct	agttttattt	gtataggaaa	4560
	tttccctgac	cctaaataat	acattttgaa	atgaaacaag	cttaciaaaga	tataatctat	4620
	tttattatgg	tttcccttgt	atctatttgt	ggtgaatgtg	ttttttaaat	ggaactatct	4680
50	ccaaattttt	ctaagactac	tatgaacagt	tttcttttaa	aattttgaga	ttaagaatgc	4740
	caggaatatt	gtcatccttt	gagctgctga	ctgccaataa	cattcttcga	tctctgggat	4800
	ttatgctcat	gaactaaatt	taagcttaag	ccataaaaata	gattagattg	ttttttaaaa	4860
55	atggatagct	cattaagaag	tgcagcaggt	taagaatttt	ttcctaaaga	ctgtatattt	4920

EP 2 770 066 B1

gaggggtttc agaattttgc attgcagtca tagaagagat ttatttcctt ttagagggg 4980
aatgaggta aataagtaaa aaagtatgct tgtaattttt attcaagaat gccagtagaa 5040
5 aattcataac gtgtatcttt aagaaaaatg agcatacatc ttaaactctt tcaatta 5097

<210> 2

<211> 1132

<212> PRT

10 <213> Homo sapiens

<400> 2

15

20

25

30

35

40

45

50

55

EP 2 770 066 B1

Met Gly Met Ala Cys Leu Thr Met Thr Glu Met Glu Gly Thr Ser Thr
 1 5 10 15
 Ser Ser Ile Tyr Gln Asn Gly Asp Ile Ser Gly Asn Ala Asn Ser Met
 5 20 25 30
 Lys Gln Ile Asp Pro Val Leu Gln Val Tyr Leu Tyr His Ser Leu Gly
 10 35 40 45
 Lys Ser Glu Ala Asp Tyr Leu Thr Phe Pro Ser Gly Glu Tyr Val Ala
 15 50 55 60
 Glu Glu Ile Cys Ile Ala Ala Ser Lys Ala Cys Gly Ile Thr Pro Val
 20 65 70 75 80
 Tyr His Asn Met Phe Ala Leu Met Ser Glu Thr Glu Arg Ile Trp Tyr
 25 85 90 95
 Pro Pro Asn His Val Phe His Ile Asp Glu Ser Thr Arg His Asn Val
 30 100 105 110
 Leu Tyr Arg Ile Arg Phe Tyr Phe Pro Arg Trp Tyr Cys Ser Gly Ser
 35 115 120 125
 Asn Arg Ala Tyr Arg His Gly Ile Ser Arg Gly Ala Glu Ala Pro Leu
 40 130 135 140
 Leu Asp Asp Phe Val Met Ser Tyr Leu Phe Ala Gln Trp Arg His Asp
 45 145 150 155 160
 Phe Val His Gly Trp Ile Lys Val Pro Val Thr His Glu Thr Gln Glu
 50 165 170 175
 Glu Cys Leu Gly Met Ala Val Leu Asp Met Met Arg Ile Ala Lys Glu
 55 180 185 190
 Asn Asp Gln Thr Pro Leu Ala Ile Tyr Asn Ser Ile Ser Tyr Lys Thr

EP 2 770 066 B1

		195						200								205
5	Phe	Leu	Pro	Lys	Cys	Ile	Arg	Ala	Lys	Ile	Gln	Asp	Tyr	His	Ile	Leu
		210					215					220				
10	Thr	Arg	Lys	Arg	Ile	Arg	Tyr	Arg	Phe	Arg	Arg	Phe	Ile	Gln	Gln	Phe
	225				230						235					240
15	Ser	Gln	Cys	Lys	Ala	Thr	Ala	Arg	Asn	Leu	Lys	Leu	Lys	Tyr	Leu	Ile
				245						250					255	
20	Asn	Leu	Glu	Thr	Leu	Gln	Ser	Ala	Phe	Tyr	Thr	Glu	Lys	Phe	Glu	Val
				260					265					270		
25	Lys	Glu	Pro	Gly	Ser	Gly	Pro	Ser	Gly	Glu	Glu	Ile	Phe	Ala	Thr	Ile
			275					280					285			
30	Ile	Ile	Thr	Gly	Asn	Gly	Gly	Ile	Gln	Trp	Ser	Arg	Gly	Lys	His	Lys
	290					295						300				
35	Glu	Ser	Glu	Thr	Leu	Thr	Glu	Gln	Asp	Leu	Gln	Leu	Tyr	Cys	Asp	Phe
	305					310					315					320
40	Pro	Asn	Ile	Ile	Asp	Val	Ser	Ile	Lys	Gln	Ala	Asn	Gln	Glu	Gly	Ser
				325						330					335	
45	Asn	Glu	Ser	Arg	Val	Val	Thr	Ile	His	Lys	Gln	Asp	Gly	Lys	Asn	Leu
				340					345					350		
50	Glu	Ile	Glu	Leu	Ser	Ser	Leu	Arg	Glu	Ala	Leu	Ser	Phe	Val	Ser	Leu
			355					360					365			
55	Ile	Asp	Gly	Tyr	Tyr	Arg	Leu	Thr	Ala	Asp	Ala	His	His	Tyr	Leu	Cys
	370					375						380				
60	Lys	Glu	Val	Ala	Pro	Pro	Ala	Val	Leu	Glu	Asn	Ile	Gln	Ser	Asn	Cys
	385					390					395					400
65	His	Gly	Pro	Ile	Ser	Met	Asp	Phe	Ala	Ile	Ser	Lys	Leu	Lys	Lys	Ala
				405						410					415	
70	Gly	Asn	Gln	Thr	Gly	Leu	Tyr	Val	Leu	Arg	Cys	Ser	Pro	Lys	Asp	Phe
				420					425					430		
75	Asn	Lys	Tyr	Phe	Leu	Thr	Phe	Ala	Val	Glu	Arg	Glu	Asn	Val	Ile	Glu
			435					440					445			

EP 2 770 066 B1

Tyr Lys His Cys Leu Ile Thr Lys Asn Glu Asn Glu Glu Tyr Asn Leu
 450 455 460
 5
 Ser Gly Thr Lys Lys Asn Phe Ser Ser Leu Lys Asp Leu Leu Asn Cys
 465 470 475 480
 10
 Tyr Gln Met Glu Thr Val Arg Ser Asp Asn Ile Ile Phe Gln Phe Thr
 485 490 495
 15
 Lys Cys Cys Pro Pro Lys Pro Lys Asp Lys Ser Asn Leu Leu Val Phe
 500 505 510
 20
 Arg Thr Asn Gly Val Ser Asp Val Pro Thr Ser Pro Thr Leu Gln Arg
 515 520 525
 25
 Pro Thr His Met Asn Gln Met Val Phe His Lys Ile Arg Asn Glu Asp
 530 535 540
 30
 Leu Ile Phe Asn Glu Ser Leu Gly Gln Gly Thr Phe Thr Lys Ile Phe
 545 550 555 560
 35
 Lys Gly Val Arg Arg Glu Val Gly Asp Tyr Gly Gln Leu His Glu Thr
 565 570 575
 40
 Glu Val Leu Leu Lys Val Leu Asp Lys Ala His Arg Asn Tyr Ser Glu
 580 585 590
 45
 Ser Phe Phe Glu Ala Ala Ser Met Met Ser Lys Leu Ser His Lys His
 595 600 605
 50
 Leu Val Leu Asn Tyr Gly Val Cys Val Cys Gly Asp Glu Asn Ile Leu
 610 615 620
 55
 Val Gln Glu Phe Val Lys Phe Gly Ser Leu Asp Thr Tyr Leu Lys Lys
 625 630 635 640
 60
 Asn Lys Asn Cys Ile Asn Ile Leu Trp Lys Leu Glu Val Ala Lys Gln
 645 650 655
 65
 Leu Ala Trp Ala Met His Phe Leu Glu Glu Asn Thr Leu Ile His Gly
 660 665 670
 70
 Asn Val Cys Ala Lys Asn Ile Leu Leu Ile Arg Glu Glu Asp Arg Lys
 675 680 685
 75
 Thr Gly Asn Pro Pro Phe Ile Lys Leu Ser Asp Pro Gly Ile Ser Ile
 690 695 700

EP 2 770 066 B1

Thr Val Leu Pro Lys Asp Ile Leu Gln Glu Arg Ile Pro Trp Val Pro
 705 710 715 720
 5 Pro Glu Cys Ile Glu Asn Pro Lys Asn Leu Asn Leu Ala Thr Asp Lys
 725 730
 10 Trp Ser Phe Gly Thr Thr Leu Trp Glu Ile Cys Ser Gly Gly Asp Lys
 740 745 750
 15 Pro Leu Ser Ala Leu Asp Ser Gln Arg Lys Leu Gln Phe Tyr Glu Asp
 755 760 765
 20 Arg His Gln Leu Pro Ala Pro Lys Trp Ala Glu Leu Ala Asn Leu Ile
 770 775 780
 25 Asn Asn Cys Met Asp Tyr Glu Pro Asp Phe Arg Pro Ser Phe Arg Ala
 785 790 795 800
 30 Ile Ile Arg Asp Leu Asn Ser Leu Phe Thr Pro Asp Tyr Glu Leu Leu
 805 810 815
 35 Thr Glu Asn Asp Met Leu Pro Asn Met Arg Ile Gly Ala Leu Gly Phe
 820 825 830
 40 Ser Gly Ala Phe Glu Asp Arg Asp Pro Thr Gln Phe Glu Glu Arg His
 835 840 845
 45 Leu Lys Phe Leu Gln Gln Leu Gly Lys Gly Asn Phe Gly Ser Val Glu
 850 855 860
 50 Met Cys Arg Tyr Asp Pro Leu Gln Asp Asn Thr Gly Glu Val Val Ala
 865 870 875 880
 55 Val Lys Lys Leu Gln His Ser Thr Glu Glu His Leu Arg Asp Phe Glu
 885 890 895
 60 Arg Glu Ile Glu Ile Leu Lys Ser Leu Gln His Asp Asn Ile Val Lys
 900 905 910
 65 Tyr Lys Gly Val Cys Tyr Ser Ala Gly Arg Arg Asn Leu Lys Leu Ile
 915 920 925
 70 Met Glu Tyr Leu Pro Tyr Gly Ser Leu Arg Asp Tyr Leu Gln Lys His
 930 935 940
 75 Lys Glu Arg Ile Asp His Ile Lys Leu Leu Gln Tyr Thr Ser Gln Ile
 945 950 955 960

EP 2 770 066 B1

	Cys	Lys	Gly	Met	Glu	Tyr	Leu	Gly	Thr	Lys	Arg	Tyr	Ile	His	Arg	Asp	
					965					970					975		
5	Leu	Ala	Thr	Arg	Asn	Ile	Leu	Val	Glu	Asn	Glu	Asn	Arg	Val	Lys	Ile	
				980					985					990			
10	Gly	Asp	Phe	Gly	Leu	Thr	Lys	Val	Leu	Pro	Gln	Asp	Lys	Glu	Tyr	Tyr	
			995					1000					1005				
15	Lys	Val	Lys	Glu	Pro	Gly	Glu	Ser	Pro	Ile	Phe	Trp	Tyr	Ala	Pro		
		1010					1015					1020					
20	Glu	Ser	Leu	Thr	Glu	Ser	Lys	Phe	Ser	Val	Ala	Ser	Asp	Val	Trp		
		1025					1030					1035					
25	Ser	Phe	Gly	Val	Val	Leu	Tyr	Glu	Leu	Phe	Thr	Tyr	Ile	Glu	Lys		
		1040					1045					1050					
30	Ser	Lys	Ser	Pro	Pro	Ala	Glu	Phe	Met	Arg	Met	Ile	Gly	Asn	Asp		
		1055					1060					1065					
35	Lys	Gln	Gly	Gln	Met	Ile	Val	Phe	His	Leu	Ile	Glu	Leu	Leu	Lys		
		1070					1075					1080					
40	Asn	Asn	Gly	Arg	Leu	Pro	Arg	Pro	Asp	Gly	Cys	Pro	Asp	Glu	Ile		
		1085					1090					1095					
45	Tyr	Met	Ile	Met	Thr	Glu	Cys	Trp	Asn	Asn	Asn	Val	Asn	Gln	Arg		
		1100					1105					1110					
50	Pro	Ser	Phe	Arg	Asp	Leu	Ala	Leu	Arg	Val	Asp	Gln	Ile	Arg	Asp		
		1115					1120					1125					
55	Asn	Met	Ala	Gly													
		1130															
60	<210>	3															
	<211>	128															
	<212>	DNA															
	<213>	Homo sapiens															
65	<400>	3															
70	ataaatcaaa	ccttctagtc	ttcagaacga	atggtgtttc	tgatgtacca	acctcaccaa										60	
75	cattacagag	gcctactcat	atgaaccaa	tggtgtttca	caaatcaga	aatgaagatt										120	
80	tgatattt															128	
85	<210>	4															

EP 2 770 066 B1

<211> 135
 <212> DNA
 <213> Homo sapiens
 5 <400> 4

 aatgaaagcc ttggccaag cacttttaca aagattttta aaggcgtacg aagagaagta 60
 ggagactacg gtcaactgca tgaaacagaa gttcttttaa aagttctgga taaagcacac 120
 10 agaaactatt cagag 135

 <210> 5
 <211> 88
 15 <212> DNA
 <213> Homo sapiens

 <400> 5
 20 tctttctttg aagcagcaag tatgatgagc aagctttctc acaagcattt ggttttaaat 60
 tatggagtat gtgtctgtgg agacgaga 88

 25 <210> 6
 <211> 38
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence: Synthetic primer

 <400> 6
 35 tgtaaacga cgccagtct aaatgctgc ccccaaag 38

 <210> 7
 <211> 38
 <212> DNA
 <213> Artificial Sequence
 40 <220>
 <223> Description of Artificial Sequence: Synthetic primer

 <400> 7
 45 caggaacag ctatgacccc atgccaactg ttagcaa 38

 <210> 8
 <211> 11
 <212> DNA
 50 <213> Homo sapiens

 <400> 8
 cgtackaaga g 11
 55 <210> 9
 <211> 11
 <212> DNA
 <213> Homo sapiens

<400> 9
actacrgtca a 11

5 <210> 10
<211> 39
<212> DNA
<213> Homo sapiens

10 <400> 10
aaactattca gagwywtct kkkwmrcrrs wwkkwwraw 39

15 <210> 11
<211> 14
<212> DNA
<213> Homo sapiens

20 <400> 11
atattcyggt tcag 14

Claims

1. An isolated nucleic acid comprising at least 17 contiguous nucleotides corresponding to SEQ ID NO:1, wherein said isolated nucleic acid comprises the mutation wherein nucleotides 2271-2358 (exon 14 deletion) are deleted, wherein said nucleic acid is less than 5000 nucleotides in length.
2. The isolated nucleic acid of claim 1, wherein said nucleic acid further comprises at least one additional mutation shown in Table 2, and/or wherein said nucleic acid is labeled with a detectable label.
3. A polypeptide comprising at least 10 contiguous amino acids corresponding to SEQ ID NO: 2 in which amino acids S593-N622 are deleted, wherein said polypeptide is less than 1100 amino acids.
4. The polypeptide of claim 3, wherein said polypeptide further comprises at least one additional mutation shown in Table 2, and/or wherein said polypeptide is labeled with a detectable label.
5. A method for detecting a hematopoietic disease comprising detecting the presence or absence of a JAK2 mutation using a biological sample obtained from an individual, comprising:
 - a) evaluating a sample from the individual for the presence or absence of a mutation in JAK2 nucleic acid or JAK2 polypeptide, wherein said mutation in JAK2 nucleic acid is a deletion of nucleotides 2271-2358 (exon 14) and the mutation in JAK2 polypeptide is the deletion of amino acids S593-N622; and
 - b) identifying said individual as having a hematopoietic disease when said JAK2 nucleic acid or JAK2 polypeptide, respectively, comprises said mutation.
6. The method of claim 5, wherein the JAK2 nucleic acid is RNA.
7. The method of claims 5 or 6, wherein the individual is a patient and wherein said sample is from a biological fluid from the patient.
8. The method of any one of claims 5-7, wherein said sample is selected from the group consisting of blood, serum, and plasma.
9. The method of any one of claims 5-8, wherein said JAK2 nucleic acid or said JAK2 polypeptide further comprises at least one additional mutation shown in Table 2.
10. The method of any one of claims 5-9, wherein said hematopoietic disease is a myeloproliferative disease.

11. The method of claim 10, wherein said myeloproliferative disease is selected from the group consisting of polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, and unclassified myeloproliferative disease.
- 5 12. The method of any one of claims 5-11, wherein said evaluating step comprises amplifying JAK2 nucleic acid and hybridizing the amplified nucleic acid with a detection oligonucleotide that is capable of specifically detecting JAK2 nucleic acid under hybridization conditions.
- 10 13. The method of any one of claims 5-12, wherein said evaluating step comprises amplifying JAK2 nucleic acid and performing direct sequencing analysis of the amplified nucleic acid.
14. The method of any one of claims 5-11, wherein said evaluating step comprises using an antibody that specifically binds to the mutated JAK2 polypeptide.

15 **Patentansprüche**

- 20 1. Isolierte Nukleinsäure, die zumindest 17 zusammenhängende Nukleotide entsprechend SEQ ID NO: 1 umfasst, wobei die isolierte Nukleinsäure die Mutation umfasst, wobei die Nukleotide 2271-2358 (Exon 14 Deletion) deletiert sind, wobei die Nukleinsäure weniger als 5000 Nukleotide lang ist.
- 25 2. Isolierte Nukleinsäure nach Anspruch 1, wobei die Nukleinsäure weiterhin zumindest eine weitere Mutation, gezeigt in Tabelle 2, umfasst, und/oder wobei die Nukleinsäure mit einer detektierbaren Markierung markiert ist.
3. Polypeptid, das zumindest 10 zusammenhängende Aminosäuren entsprechend SEQ ID NO: 2 umfasst, in welchem Aminosäuren S593-N622 deletiert sind, wobei das Polypeptid weniger als 1100 Aminosäuren lang ist.
- 30 4. Polypeptid nach Anspruch 3, wobei das Polypeptid weiterhin zumindest eine weitere Mutation, gezeigt in Tabelle 2, umfasst, und/oder wobei das Polypeptid mit einer detektierbaren Markierung markiert ist.
- 35 5. Verfahren zum Nachweisen einer hämatopoetischen Erkrankung umfassend das Detektieren des Vorhandenseins oder Fehlens einer JAK2 Mutation unter Verwendung einer von einer Person erhaltenen biologischen Probe, umfassend:
- a) Auswerten einer Probe der Person auf das Vorhandensein oder Fehlen einer Mutation in JAK2 Nukleinsäure oder JAK2 Polypeptid, wobei die Mutation in der JAK2 Nukleinsäure eine Deletion der Nukleotide 2271-2358 (Exon 14) ist und die Mutation im JAK2 Polypeptid die Deletion der Aminosäuren S593-N622 ist; und
- b) Identifizieren der Person als an einer hämatopoetischen Erkrankung erkrankt, wenn die JAK2 Nukleinsäure bzw. das JAK2 Polypeptid diese Mutation umfasst.
- 40 6. Verfahren nach Anspruch 5, wobei die JAK2 Nukleinsäure RNA ist.
7. Verfahren nach Anspruch 5 oder 6, wobei die Person ein Patient ist und wobei die Probe von einer biologischen Flüssigkeit des Patienten stammt.
- 45 8. Verfahren nach einem der Ansprüche 5-7, wobei die Probe aus der Gruppe ausgewählt wird, die aus Blut, Serum und Plasma besteht.
9. Verfahren nach einem der Ansprüche 5-8, wobei die JAK2 Nukleinsäure oder das JAK2 Polypeptid weiterhin zumindest eine weitere Mutation, gezeigt in Tabelle 2, umfasst.
- 50 10. Verfahren nach einem der Ansprüche 5-9, wobei die hämatopoetische Erkrankung eine myeloproliferative Erkrankung ist.
- 55 11. Verfahren nach Anspruch 10, wobei die myeloproliferative Erkrankung aus der Gruppe ausgewählt wird, die aus Polycythaemia vera, essentielle Thrombozythämie, idiopathische Myelofibrose und nicht klassifizierte myeloproliferative Erkrankung besteht.
12. Verfahren nach einem der Ansprüche 5-11, wobei der Auswertungsschritt das Amplifizieren von JAK2 Nukleinsäure

EP 2 770 066 B1

und Hybridisieren der amplifizierten Nukleinsäure mit einem Detektions-Oligonukleotid, das in der Lage ist, spezifisch JAK2 Nukleinsäure unter Hybridisierungsbedingungen zu detektieren, umfasst.

5 13. Verfahren nach einem der Ansprüche 5-12, wobei der Auswertungsschritt das Amplifizieren von JAK2 Nukleinsäure und Durchführen direkter Sequenzierungsanalyse der amplifizierten Nukleinsäure, umfasst.

14. Verfahren nach einem der Ansprüche 5-11, wobei der Auswertungsschritt das Verwenden eines Antikörpers, der spezifisch an das mutierte JAK2 Polypeptid bindet, umfasst.

10 Revendications

15 1. Acide nucléique isolé comprenant au moins 17 nucléotides contigus correspondant à la SÉQ ID NO :1, dans lequel ledit acide nucléique isolé comprend la mutation dans laquelle les nucléotides 2271-2358 (délétion de l'exone 14) sont supprimés, dans lequel ledit acide nucléique a une longueur de moins de 5000 nucléotides.

20 2. Acide nucléique selon la revendication 1, dans lequel ledit acide nucléique comprend, en outre, au moins une mutation supplémentaire représentée dans le Tableau 2, et/ou dans lequel ledit acide nucléique est marqué avec un marqueur détectable.

3. Polypeptide comprenant au moins 10 acides aminés contigus correspondant à la SÉQ ID NO :2, dans lequel les acides aminés S593-N622 sont supprimés, dans lequel ledit polypeptide compte moins de 1100 acides aminés.

25 4. Polypeptide selon la revendication 3, dans lequel ledit polypeptide comprend, en outre, au moins une mutation supplémentaire représentée dans le Tableau 2, et/ou dans lequel ledit polypeptide est marqué avec un marqueur détectable.

30 5. Méthode de détection d'une maladie hématopoïétique comprenant l'étape qui consiste à détecter la présence ou l'absence d'une mutation JAK2 en utilisant un échantillon biologique obtenu d'un individu, comprenant les étapes qui consistent à :

35 a) évaluer un échantillon prélevé chez l'individu pour détecter la présence ou l'absence d'une mutation dans l'acide nucléique JAK2 ou le polypeptide JAK2, dans lequel ladite mutation dans l'acide nucléique JAK2 est une délétion des nucléotides 2271-2358 (exone 14) et la mutation dans le polypeptide JAK2 est la délétion des acides aminés S593-N622 ; et

b) identifier que ledit individu est atteint d'une maladie hématopoïétique quand ledit acide nucléique JAK2 ou le polypeptide JAK2, respectivement, comprend ladite mutation.

40 6. Méthode selon la revendication 5, dans laquelle l'acide nucléique JAK2 est l'ARN.

7. Méthode selon la revendication 5 ou 6, dans laquelle l'individu est un patient et dans laquelle ledit échantillon provient d'un liquide physiologique de l'organisme prélevé chez le patient.

45 8. Méthode selon l'une quelconque des revendications 5 à 7, dans laquelle ledit échantillon est sélectionné parmi le groupe constitué par le sang, le sérum et le plasma.

9. Méthode selon l'une quelconque des revendications 5 à 8, dans laquelle ledit acide nucléique JAK2 ou ledit polypeptide JAK2 comprend, en outre, au moins une mutation supplémentaire représentée dans le Tableau 2.

50 10. Méthode selon l'une quelconque des revendications 5 à 9, dans laquelle ladite maladie hématopoïétique est une maladie myéloproliférative.

55 11. Méthode selon la revendication 10, dans laquelle ladite maladie myéloproliférative est sélectionnée parmi le groupe constitué par la polyglobulie vraie, la thrombocythémie essentielle, la myélofibrose idiopathique, et une maladie myéloproliférative non classifiée.

12. Méthode selon l'une quelconque des revendications 5 à 11, dans laquelle ladite étape d'évaluation comprend l'amplification de l'acide nucléique JAK2 et l'hybridation de l'acide nucléique amplifié avec un oligonucléotide de

EP 2 770 066 B1

détection qui est capable de détecter spécifiquement l'acide nucléique JAK2 sous des conditions d'hybridation.

5 13. Méthode selon l'une quelconque des revendications 5 à 12, dans laquelle ladite étape d'évaluation comprend l'amplification de l'acide nucléique JAK2 et la réalisation d'une analyse de séquençage direct de l'acide nucléique amplifié.

10 14. Méthode selon l'une quelconque des revendications 5 à 11, dans laquelle ladite étape d'évaluation consiste à utiliser un anticorps qui se lie spécifiquement au polypeptide JAK2 muté.

10

15

20

25

30

35

40

45

50

55

Series of Representative Sequencing Chromatograms




FIG. 1(A)




FIG. 1(B)





FIG. 1(C)

Diagram of JAK2 Gene Structure and Mutations



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 408241 A [0054]
- US 20070248961 A [0054]
- US 5639611 A [0063]
- WO 61110501 A [0098]

Non-patent literature cited in the description

- **SCHINDLER, C.W.** *J. Clin. Invest.*, 2002, vol. 109, 1133-1137 [0003]
- **TEFFERI ; GILLILAND.** *Mayo Clin. Proc.*, 2005, vol. 80, 947-958 [0003]
- **GIORDANETTO ; KROEMER.** *Protein Engineering*, 2002, vol. 15 (9), 727-737 [0003]
- **NELSON, M.E. ; STEENSMA, D.P.** *Leuk. Lymphoma*, 2006, vol. 47, 177-194 [0003]
- **VAINCHENKER ; CONSTANTINESCU.** *Hematology. American Society of Hematology*, 2005, 195-200 [0004]
- **SMITH, C.A. et al.** *Human Pathology*, 2008, vol. 39, 795-810 [0005]
- **BAXTER et al.** *Lancet*, 2005, vol. 365, 1054-1060 [0005] [0006]
- **JAMES et al.** *Nature*, 2005, vol. 438, 1144-1148 [0005] [0006]
- **ZHAO et al.** *J. Biol. Chem.*, 2005, vol. 280 (24), 22788-22792 [0005] [0006]
- **LEVINE et al.** *Cancer Cell*, 2005, vol. 7, 387-397 [0005] [0006]
- **KRALOVICS et al.** *New Eng. J. Med.*, 2005, vol. 352 (17), 1779-1790 [0005] [0006]
- **JONES et al.** *Blood*, 2005, vol. 106, 2162-2168 [0005]
- **STEENSMA et al.** *Blood*, 2005, vol. 106, 1207-2109 [0005]
- **KAUSHANSKY.** *Hematology. Am Soc Hematol Educ Program*, 2005, 533-7 [0006]
- **SAHARINEN et al.** *Mol Cell Biol*, 2000, vol. 20, 3387-3395 [0007]
- **SAHARINEN et al.** *Mol. Biol Cell*, 2003, vol. 14, 1448-1459 [0007]
- **SCOTT et al.** *N Engl J Med*, 2007, vol. 356, 459-468 [0007] [0083]
- **LI et al.** *Blood*, 2008, vol. 111, 3863-3866 [0007]
- **ALBIERO et al.** *American J. of Hematology*, 2008, vol. 83 (7), 603-604 [0008]
- **BESSES et al.** *Blood. American Society of Hematology*, 2007, vol. 110, 746a [0008]
- **INAMI et al.** *Leukemia*, 2008, vol. 22 (1), 216 [0008]
- **MANIATIS et al.** *Molecular Cloning, A Laboratory Manual.* Cold Spring Harbor Laboratory Press, 1989, 16.54 [0057]
- **STROUN, M. et al.** *Oncology*, 1989, vol. 46, 318-322 [0059]
- **RASHTCHIAN, A.** *PCR Methods Applic.*, 1994, vol. 4, S83-S91 [0059]
- **BOOM, R. et al.** *J. Clin. Micro.*, 1990, vol. 28, 495-503 [0060]
- **CHEUNG, R. C. et al.** *J. Clin. Micro.*, 1994, vol. 32, 2593-2597 [0060]
- **CHOMCZYNSKI, P. ; SACCHI, N.** *Analytical Biochemistry*, 1987, vol. 162, 156-159 [0061]
- **CHIRGWIN, J. M. et al.** *Biochemistry*, 1979, vol. 18, 5294-5299 [0062]
- **FOURNIE, G. J. et al.** *Analytical Biochemistry*, 1986, vol. 158, 250-256 [0062]
- **WANG, A. M. et al.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 9717-9721 [0063]
- **KARET, F. E. et al.** *Analytical Biochemistry*, 1994, vol. 220, 384-390 [0063]
- **WIEDMANN et al.** *PCR Methods Appl.*, 1994, vol. 3, 551-564 [0063]
- *Current Protocols in Immunology.* John Wiley & Sons [0071]
- **HAGE.** *Immunoassays. Anal Chem.*, 15 June 1999, vol. 71 (12), 294R-304R [0071]
- **HEID et al.** *Genome Res*, 1996, vol. 6, 986-994 [0077]
- **TYAGI et al.** *Nature Biotechnology*, 1998, vol. 16, 49-53 [0077]

专利名称(译)	用于检测JAK2核酸中的突变的组合物和方法		
公开(公告)号	EP2770066B1	公开(公告)日	2016-03-09
申请号	EP2014161006	申请日	2009-10-22
[标]申请(专利权)人(译)	奎斯特诊断投资公司		
申请(专利权)人(译)	Quest Diagnostics公司投资INCORPORATED		
当前申请(专利权)人(译)	Quest Diagnostics公司投资INCORPORATED		
[标]发明人	ALBITAR MAHER MA WANLONG		
发明人	ALBITAR, MAHER MA, WANLONG		
IPC分类号	C12Q1/68 G01N33/53		
CPC分类号	C12N9/1205 C12Q1/6883 C12Q2600/118 C12Q2600/156 C12Y207/10001 G01N33/573 G01N2333/91205 G01N2800/22 G01N2800/56		
优先权	61/110501 2008-10-31 US 12/503318 2009-07-15 US		
其他公开文献	EP2770066A2 EP2770066A3		
外部链接	Espacenet		

摘要(译)	<p>本文公开的发明基于JAK2基因和JAK2蛋白中的新突变的鉴定。本发明提供了用于诊断造血疾病的组合物和方法，包括例如骨髓增生性疾病。本发明还提供了用于确定被诊断患有造血疾病的个体的预后的组合物和方法。</p>	<pre> ctgcaggaag gagagaggaa gaggagcaga agggggcagc agcggacgcc gctaacggcc 60 tccctcggcg ctgacaggct gggcggcgc cgggtcgcgt tgggtgttcg cgtcgccact 120 tcggcttctc ggcgggtcgg gccctcggc ccgggcttgc ggcgcgcgtc ggggtgagg 180 gtcgtcgcg cgcagggaga ggcctggtcc tcgctgccga gggatgtgag tgggagctga 240 gcccaactg gaggccccc gaggccccc cctggaggte gttcagagcc gtgccgcccc 300 cgggcttcg cagacctga ccgcccggg agggaccgcc cctgcgggct cgagggcgcg 360 ctctggtcgc ccgatctgtg tagccggtt cagaagcagc caacaggaac aagatgtgaa 420 ctgtttctct tctgcagaaa aagaggctct tctcctcct cccgcgacgg caaatgttct 480 gaaaaagact ctgcatgga atggcctgct ttaogatgac agaatggag ggaacatcca 540 cctctctat atatcagaat ggtgatatt ctggaatgc caattctatg aagcaaatag 600 atccagttct tcaggtgtat cttaccatt ccoctgggaa atctgaggca gattatctga 660 cctttcatc tggggagtat gttgcagaag aaatctgtat tgctgcttct aaagcttctg 720 gtatcacacc tgtgtatcat aatagtctt ctttaatgag tgaacagaa aggatctggt 780 atccacccaa ccatgtcttc catatagatg agtoaaccaag gcataatgta ctctacagaa 840 taagatttta ctttctcgt tggtattgca gtggcagcaa cagagcctat cggcatggaa 900 tatctcagag tgcggaagct cctctcttg atgacttctg catgtcttac ctcttctc 960 agtggcgcca tgattttgtg cacggatgga taaaagtacc tgtgactcat gaaacacag 1020 aagaatgtct tgggatggca gtgttagata tgatgagaat agccaagaa aacgatcaaa 1080 cccactggc catctataac tctatcagct acaagacatt cttaccaaaa tgtattcgag 1140 </pre>
-------	--	--